https://trial.medpath.com/news/ema-official-reports-on-scientific-advice-pilots-for-high-risk-and-orphan-devices-raps 2024-10-28T20:53:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-official-reports-on-scientific-advice-pilots-for-high-risk-and-orphan-devices-raps 2024-10-28T20:53:24+00:00 weekly 0.7 https://trial.medpath.com/news/novel-prostate-cancer-treatment-increases-overall-newswise 2024-10-28T20:48:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-prostate-cancer-treatment-increases-overall-newswise 2024-10-28T20:48:39+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-alert-searches-spiking-for-these-stocks-today-markets-insider 2024-10-28T20:38:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-alert-searches-spiking-for-these-stocks-today-markets-insider 2024-10-28T20:38:14+00:00 weekly 0.7 https://trial.medpath.com/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3 2024-10-28T20:33:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3 2024-10-28T20:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/what-3-big-trials-mean-for-breast-cancer-practice-oncology-news-central 2024-10-28T20:28:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-3-big-trials-mean-for-breast-cancer-practice-oncology-news-central 2024-10-28T20:28:49+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T20:26:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T20:26:49+00:00 weekly 0.7 https://trial.medpath.com/news/merck-moderna-launch-phase-3-trial-evaluating-adjuvant-v940-keytruda-combo 2024-10-28T20:26:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-moderna-launch-phase-3-trial-evaluating-adjuvant-v940-keytruda-combo 2024-10-28T20:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-oral-antibiotic-for-urinary-tract-infections-cidrap 2024-10-28T20:20:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-oral-antibiotic-for-urinary-tract-infections-cidrap 2024-10-28T20:20:12+00:00 weekly 0.7 https://trial.medpath.com/news/wvu-rockefeller-neuroscience-institute-receives-state-funding-to-expand-research-and 2024-10-28T20:16:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wvu-rockefeller-neuroscience-institute-receives-state-funding-to-expand-research-and 2024-10-28T20:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-after-neoadjuvant-keytruda-and-chemotherapy-in-patients-with-certain-types-of-non-small-cell-lung-cancer-nsclc 2024-10-28T19:10:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-combination-with-keytruda-pembrolizumab-after-neoadjuvant-keytruda-and-chemotherapy-in-patients-with-certain-types-of-non-small-cell-lung-cancer-nsclc 2024-10-28T19:10:09+00:00 weekly 0.7 https://trial.medpath.com/news/ide397-shows-preliminary-efficacy-in-mtap-nsclc-and-urothelial-cancer 2024-10-28T19:07:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ide397-shows-preliminary-efficacy-in-mtap-nsclc-and-urothelial-cancer 2024-10-28T19:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/implantable-microparticles-can-deliver-two-cancer-therapies-at-once-mit-news 2024-10-28T18:54:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implantable-microparticles-can-deliver-two-cancer-therapies-at-once-mit-news 2024-10-28T18:54:27+00:00 weekly 0.7 https://trial.medpath.com/news/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-chronic 2024-10-28T18:31:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-chronic 2024-10-28T18:31:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-oks-new-drug-for-urinary-tract-infections-webmd 2024-10-28T18:29:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-oks-new-drug-for-urinary-tract-infections-webmd 2024-10-28T18:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-pharmaceuticals-swot-analysis-stock-poised-for-growth-amid-fda-approvals 2024-10-28T18:22:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-pharmaceuticals-swot-analysis-stock-poised-for-growth-amid-fda-approvals 2024-10-28T18:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-signs-global-license-agreement-with-monte-rosa-therapeutics-worth-up-to-2-1 2024-10-28T18:19:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-signs-global-license-agreement-with-monte-rosa-therapeutics-worth-up-to-2-1 2024-10-28T18:19:46+00:00 weekly 0.7 https://trial.medpath.com/news/the-start-center-for-cancer-research-and-fundacion-rioja-salud-announce-pr-newswire 2024-10-28T18:04:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-start-center-for-cancer-research-and-fundacion-rioja-salud-announce-pr-newswire 2024-10-28T18:04:07+00:00 weekly 0.7 https://trial.medpath.com/news/monte-rosa-scores-2-1b-novartis-deal-for-molecular-glue-degraders-bioworld 2024-10-28T17:55:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monte-rosa-scores-2-1b-novartis-deal-for-molecular-glue-degraders-bioworld 2024-10-28T17:55:14+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-formulated-shows-greater-efficacy-than-fda-approved-drug-benzinga 2024-10-28T17:54:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-formulated-shows-greater-efficacy-than-fda-approved-drug-benzinga 2024-10-28T17:54:51+00:00 weekly 0.7 https://trial.medpath.com/news/eyepoint-pharmaceuticals-reports-positive-16-week-interim-results-from-phase-2-verona 2024-10-28T17:52:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyepoint-pharmaceuticals-reports-positive-16-week-interim-results-from-phase-2-verona 2024-10-28T17:52:48+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-develop-a-digital-twin-model-to-predict-cancer-treatment-responses 2024-10-28T17:45:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scientists-develop-a-digital-twin-model-to-predict-cancer-treatment-responses 2024-10-28T17:45:30+00:00 weekly 0.7 https://trial.medpath.com/news/rmc-9805-triggers-tumor-regressions-in-kras-g12c-mutant-pancreatic-cancer 2024-10-28T17:36:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rmc-9805-triggers-tumor-regressions-in-kras-g12c-mutant-pancreatic-cancer 2024-10-28T17:36:39+00:00 weekly 0.7 https://trial.medpath.com/news/omvoh-achieves-long-term-remission-symptom-improvement-for-ulcerative-colitis-crohn 2024-10-28T17:34:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omvoh-achieves-long-term-remission-symptom-improvement-for-ulcerative-colitis-crohn 2024-10-28T17:34:54+00:00 weekly 0.7 https://trial.medpath.com/news/the-debate-over-the-predictive-utility-of-pd-l1-low-expression-is-ongoing-in-escc 2024-10-28T17:31:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-debate-over-the-predictive-utility-of-pd-l1-low-expression-is-ongoing-in-escc 2024-10-28T17:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-fabhalta-shows-promise-in-phase-3-kidney-disease-trial 2024-10-28T17:28:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-fabhalta-shows-promise-in-phase-3-kidney-disease-trial 2024-10-28T17:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/ugn-102-data-published-in-journal-of-urology-as-fda-weighs-nmibc-approval 2024-10-28T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ugn-102-data-published-in-journal-of-urology-as-fda-weighs-nmibc-approval 2024-10-28T17:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-explores-nalmefene-and-naloxone-for-reversal-of-respiratory-depression 2024-10-28T17:06:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-explores-nalmefene-and-naloxone-for-reversal-of-respiratory-depression 2024-10-28T17:06:44+00:00 weekly 0.7 https://trial.medpath.com/news/complement-inhibitors-clinical-trial-pipeline-analysis-40-globenewswire 2024-10-28T17:06:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/complement-inhibitors-clinical-trial-pipeline-analysis-40-globenewswire 2024-10-28T17:06:07+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-fgfr3-selective-inhibitor-shows-promise-in-urothelial-cancer 2024-10-28T17:04:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-fgfr3-selective-inhibitor-shows-promise-in-urothelial-cancer 2024-10-28T17:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/movano-to-respond-to-fda-questions-as-part-of-eviemed-final-review-phase 2024-10-28T17:03:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/movano-to-respond-to-fda-questions-as-part-of-eviemed-final-review-phase 2024-10-28T17:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-er-stress-sensor-restores-immunogenicity-of-chemotherapy-nature-reviews-immunology 2024-10-28T16:57:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeting-er-stress-sensor-restores-immunogenicity-of-chemotherapy-nature-reviews-immunology 2024-10-28T16:57:51+00:00 weekly 0.7 https://trial.medpath.com/news/why-is-moderna-stock-trading-higher-on-monday-benzinga 2024-10-28T16:50:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/why-is-moderna-stock-trading-higher-on-monday-benzinga 2024-10-28T16:50:21+00:00 weekly 0.7 https://trial.medpath.com/news/delta-fly-pharma-inc-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml-patients 2024-10-28T16:45:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delta-fly-pharma-inc-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml-patients 2024-10-28T16:45:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-fast-tracks-hc-7366-in-relapsed-refractory-acute-myeloid-leukemia 2024-10-28T16:38:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-fast-tracks-hc-7366-in-relapsed-refractory-acute-myeloid-leukemia 2024-10-28T16:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/yes-we-can-bridgebio-shares-positive-gene-therapy-data-in-canavan-trial 2024-10-28T16:26:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yes-we-can-bridgebio-shares-positive-gene-therapy-data-in-canavan-trial 2024-10-28T16:26:29+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-may-cut-alzheimer-s-risk-in-type-2-diabetes-inside-precision-medicine 2024-10-28T16:26:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-may-cut-alzheimer-s-risk-in-type-2-diabetes-inside-precision-medicine 2024-10-28T16:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharmaceuticals-swot-analysis-rare-epilepsy-drug-maker-s-stock-faces-pivotal-moment 2024-10-28T16:17:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marinus-pharmaceuticals-swot-analysis-rare-epilepsy-drug-maker-s-stock-faces-pivotal-moment 2024-10-28T16:17:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-rsv-vaccine-for-at-risk-adults-younger-than-50-copd-news-today 2024-10-28T16:15:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-rsv-vaccine-for-at-risk-adults-younger-than-50-copd-news-today 2024-10-28T16:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/ai-for-detection-of-diastolic-dysfunction-gains-fda-breakthrough-device-designation-healio 2024-10-28T16:06:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-for-detection-of-diastolic-dysfunction-gains-fda-breakthrough-device-designation-healio 2024-10-28T16:06:18+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-plc-itrm-u-s-fda-approval-of-orlynvah-call-transcript 2024-10-28T16:04:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-plc-itrm-u-s-fda-approval-of-orlynvah-call-transcript 2024-10-28T16:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/american-academy-of-ophthalmology-oct-18-21-healthday 2024-10-28T16:01:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/american-academy-of-ophthalmology-oct-18-21-healthday 2024-10-28T16:01:49+00:00 weekly 0.7 https://trial.medpath.com/news/mmv-and-quotient-sciences-initiate-clinical-trial-for-long-acting-malaria-preventive 2024-10-28T15:52:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mmv-and-quotient-sciences-initiate-clinical-trial-for-long-acting-malaria-preventive 2024-10-28T15:52:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-de-novo-authorisation-for-distalmotion-s-dexter-surgical-robot 2024-10-28T15:45:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-de-novo-authorisation-for-distalmotion-s-dexter-surgical-robot 2024-10-28T15:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-induction-chemotherapy-to-standard-chemoradiotherapy-in-locally-advanced 2024-10-28T15:41:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-induction-chemotherapy-to-standard-chemoradiotherapy-in-locally-advanced 2024-10-28T15:41:46+00:00 weekly 0.7 https://trial.medpath.com/news/is-medical-cannabis-for-children-under-18-a-good-idea-university-of-cincinnati 2024-10-28T15:40:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/is-medical-cannabis-for-children-under-18-a-good-idea-university-of-cincinnati 2024-10-28T15:40:03+00:00 weekly 0.7 https://trial.medpath.com/news/monte-rosa-joins-with-novartis-in-molecular-glue-drug-deal-biopharma-dive 2024-10-28T15:39:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monte-rosa-joins-with-novartis-in-molecular-glue-drug-deal-biopharma-dive 2024-10-28T15:39:36+00:00 weekly 0.7 https://trial.medpath.com/news/harvard-apparatus-regenerative-technology-announces-strategic-collaboration-with-biospace 2024-10-28T15:37:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harvard-apparatus-regenerative-technology-announces-strategic-collaboration-with-biospace 2024-10-28T15:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T15:37:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T15:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/bipolar-disorder-manic-depression-pipeline-assessment-2024-openpr-com 2024-10-28T15:36:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bipolar-disorder-manic-depression-pipeline-assessment-2024-openpr-com 2024-10-28T15:36:19+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-plus-targeted-therapy-for-anaplastic-thyroid-carcinoma-the-asco-post 2024-10-28T15:35:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-plus-targeted-therapy-for-anaplastic-thyroid-carcinoma-the-asco-post 2024-10-28T15:35:55+00:00 weekly 0.7 https://trial.medpath.com/news/respiratory-syncytial-virus-pipeline-2024-clinical-trials-assessment-fda-approvals 2024-10-28T15:32:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/respiratory-syncytial-virus-pipeline-2024-clinical-trials-assessment-fda-approvals 2024-10-28T15:32:16+00:00 weekly 0.7 https://trial.medpath.com/news/evolved-early-avr-fails-to-help-asymptomatic-as-patients-with-fibrosis-tctmd-com 2024-10-28T15:25:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolved-early-avr-fails-to-help-asymptomatic-as-patients-with-fibrosis-tctmd-com 2024-10-28T15:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-drug-approved-in-the-eu-for-rare-immune-disease 2024-10-28T15:24:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-drug-approved-in-the-eu-for-rare-immune-disease 2024-10-28T15:24:36+00:00 weekly 0.7 https://trial.medpath.com/news/top-stocks-to-buy-now-2-biotech-stocks-to-watch-stockmarket-com 2024-10-28T15:19:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-stocks-to-buy-now-2-biotech-stocks-to-watch-stockmarket-com 2024-10-28T15:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/bora-acquires-rare-diseases-drugmaker-pyros-pharmaceuticals 2024-10-28T15:16:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bora-acquires-rare-diseases-drugmaker-pyros-pharmaceuticals 2024-10-28T15:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T15:16:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T15:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/large-language-model-influence-on-diagnostic-reasoning-a-randomized-clinical-trial 2024-10-28T15:14:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/large-language-model-influence-on-diagnostic-reasoning-a-randomized-clinical-trial 2024-10-28T15:14:31+00:00 weekly 0.7 https://trial.medpath.com/news/with-new-diversity-guidance-ehr-data-plus-ai-will-be-critical-biopharma-dive 2024-10-28T15:11:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-new-diversity-guidance-ehr-data-plus-ai-will-be-critical-biopharma-dive 2024-10-28T15:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T15:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T15:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/uae-s-clinical-trials-space-matures-with-experience-from-covid-19 2024-10-28T15:05:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uae-s-clinical-trials-space-matures-with-experience-from-covid-19 2024-10-28T15:05:36+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-polygenic-scores-to-hypertension-treatment-outcomes-medical-xpress 2024-10-28T15:03:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-links-polygenic-scores-to-hypertension-treatment-outcomes-medical-xpress 2024-10-28T15:03:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-odd-status-to-mdl-101-for-lama2-cmd-treatment 2024-10-28T15:02:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-odd-status-to-mdl-101-for-lama2-cmd-treatment 2024-10-28T15:02:09+00:00 weekly 0.7 https://trial.medpath.com/news/findings-and-recommendations-of-the-moh-committee-of-inquiry-nni-ministry-of-health 2024-10-28T15:00:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/findings-and-recommendations-of-the-moh-committee-of-inquiry-nni-ministry-of-health 2024-10-28T15:00:45+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-28T14:57:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-28T14:57:48+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-may-cut-alzheimer-s-risk-in-type-2-diabetes-healthleaders-media 2024-10-28T14:57:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-may-cut-alzheimer-s-risk-in-type-2-diabetes-healthleaders-media 2024-10-28T14:57:10+00:00 weekly 0.7 https://trial.medpath.com/news/cardiol-therapeutics-initiates-phase-ii-iii-clinical-trial-for-recurrent-pericarditis 2024-10-28T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cardiol-therapeutics-initiates-phase-ii-iii-clinical-trial-for-recurrent-pericarditis 2024-10-28T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/shifamed-s-adona-medical-initiates-first-in-human-interatrial-shunt-study-massdevice 2024-10-28T14:53:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shifamed-s-adona-medical-initiates-first-in-human-interatrial-shunt-study-massdevice 2024-10-28T14:53:04+00:00 weekly 0.7 https://trial.medpath.com/news/primary-chemoablation-of-recurrent-low-grade-intermediate-risk-nonmuscle-invasive 2024-10-28T14:49:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/primary-chemoablation-of-recurrent-low-grade-intermediate-risk-nonmuscle-invasive 2024-10-28T14:49:00+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-launches-first-in-class-drug-to-treat-chronic-constipation-in-india 2024-10-28T14:44:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-reddy-s-launches-first-in-class-drug-to-treat-chronic-constipation-in-india 2024-10-28T14:44:40+00:00 weekly 0.7 https://trial.medpath.com/news/accord-biopharma-announces-fda-approval-of-imuldosa-ustekinumab-srlf-mondaq 2024-10-28T14:41:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accord-biopharma-announces-fda-approval-of-imuldosa-ustekinumab-srlf-mondaq 2024-10-28T14:41:35+00:00 weekly 0.7 https://trial.medpath.com/news/christine-n-kay-md-tease-trials-show-promise-of-gildeuretinol-for-stargardt 2024-10-28T14:40:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/christine-n-kay-md-tease-trials-show-promise-of-gildeuretinol-for-stargardt 2024-10-28T14:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/christine-n-kay-md-tease-trials-show-promise-of-gildeuretinol-for-stargardt-hcplive 2024-10-28T14:40:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/christine-n-kay-md-tease-trials-show-promise-of-gildeuretinol-for-stargardt-hcplive 2024-10-28T14:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/coya-therapeutics-announces-conference-call-to-report-results-from-an-investigator-biospace 2024-10-28T14:38:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/coya-therapeutics-announces-conference-call-to-report-results-from-an-investigator-biospace 2024-10-28T14:38:51+00:00 weekly 0.7 https://trial.medpath.com/news/sparrow-pharmaceuticals-announces-completion-of-phase-2-trial-and-fda-orphan-drug 2024-10-28T14:38:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sparrow-pharmaceuticals-announces-completion-of-phase-2-trial-and-fda-orphan-drug 2024-10-28T14:38:50+00:00 weekly 0.7 https://trial.medpath.com/news/envision-trial-results-published-in-the-journal-of-urology-report-82-3-duration-of-biospace 2024-10-28T14:38:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/envision-trial-results-published-in-the-journal-of-urology-report-82-3-duration-of-biospace 2024-10-28T14:38:50+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-the-perioperative-treatment-setting-in-lung-cancer-targeted-oncology 2024-10-28T14:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-the-perioperative-treatment-setting-in-lung-cancer-targeted-oncology 2024-10-28T14:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/truist-holds-buy-on-biogen-shares-price-target-steady-on-complete-results-investing-com 2024-10-28T14:23:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/truist-holds-buy-on-biogen-shares-price-target-steady-on-complete-results-investing-com 2024-10-28T14:23:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-of-orlynvah-for-urinary-tract-infections-marks-milestone-for-iterum-paves 2024-10-28T14:23:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-of-orlynvah-for-urinary-tract-infections-marks-milestone-for-iterum-paves 2024-10-28T14:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-chronic 2024-10-28T14:21:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/product-launch-modius-sleep-fda-cleared-non-invasive-device-that-treats-chronic 2024-10-28T14:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T14:14:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T14:14:56+00:00 weekly 0.7 https://trial.medpath.com/news/delayed-antibody-treatment-may-improve-efficacy-of-mrna-vaccines-news-center 2024-10-28T14:14:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delayed-antibody-treatment-may-improve-efficacy-of-mrna-vaccines-news-center 2024-10-28T14:14:41+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-biosimilar-ranibizumab-optimab-r-versus-in-opth 2024-10-28T14:11:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-biosimilar-ranibizumab-optimab-r-versus-in-opth 2024-10-28T14:11:46+00:00 weekly 0.7 https://trial.medpath.com/news/amneal-obtains-fda-ok-for-pyridostigmine-bromide-er-tablets-drug-store-news 2024-10-28T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amneal-obtains-fda-ok-for-pyridostigmine-bromide-er-tablets-drug-store-news 2024-10-28T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/rapid-blood-cancer-diagnostic-could-speed-decisions-and-save-lives-onclive 2024-10-28T14:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapid-blood-cancer-diagnostic-could-speed-decisions-and-save-lives-onclive 2024-10-28T14:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/collaborative-effort-to-conduct-a-study-aimed-at-improving-the-diagnosis-of-alzheimer-s-and 2024-10-28T14:06:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/collaborative-effort-to-conduct-a-study-aimed-at-improving-the-diagnosis-of-alzheimer-s-and 2024-10-28T14:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/will-the-upcoming-trial-updates-on-elritercept-revive-kros-s-momentum-rttnews 2024-10-28T13:56:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/will-the-upcoming-trial-updates-on-elritercept-revive-kros-s-momentum-rttnews 2024-10-28T13:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T13:43:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T13:43:57+00:00 weekly 0.7 https://trial.medpath.com/news/sylvester-physician-scientists-find-new-target-for-cancer-treatment-inventum 2024-10-28T13:35:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sylvester-physician-scientists-find-new-target-for-cancer-treatment-inventum 2024-10-28T13:35:07+00:00 weekly 0.7 https://trial.medpath.com/news/distalmotion-wins-fda-de-novo-nod-for-dexter-surgical-robot-massdevice 2024-10-28T13:31:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/distalmotion-wins-fda-de-novo-nod-for-dexter-surgical-robot-massdevice 2024-10-28T13:31:14+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T13:30:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T13:30:32+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-completes-phase-iii-randomized-double-blind-globenewswire 2024-10-28T13:22:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-completes-phase-iii-randomized-double-blind-globenewswire 2024-10-28T13:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/delfi-diagnostics-working-with-incendia-therapeutics-to-employ-advanced-treatment 2024-10-28T13:21:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delfi-diagnostics-working-with-incendia-therapeutics-to-employ-advanced-treatment 2024-10-28T13:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/delta-fly-pharma-inc-announces-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml 2024-10-28T13:16:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delta-fly-pharma-inc-announces-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml 2024-10-28T13:16:44+00:00 weekly 0.7 https://trial.medpath.com/news/harvard-apparatus-regenerative-technology-announces-strategic-collaboration-with-stock-titan 2024-10-28T13:16:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harvard-apparatus-regenerative-technology-announces-strategic-collaboration-with-stock-titan 2024-10-28T13:16:02+00:00 weekly 0.7 https://trial.medpath.com/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T13:15:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biocardia-completes-phase-iii-randomized-double-blind-controlled-trial-of-autologous 2024-10-28T13:15:54+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-secures-key-fda-meeting-to-advance-its-phase-3-als-trial-and-nda-submission 2024-10-28T13:13:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-secures-key-fda-meeting-to-advance-its-phase-3-als-trial-and-nda-submission 2024-10-28T13:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacogenomic-study-of-selected-genes-and-its-association-with-amlod-dove-medical-press 2024-10-28T13:11:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacogenomic-study-of-selected-genes-and-its-association-with-amlod-dove-medical-press 2024-10-28T13:11:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-and017-for-the-treatment-of-sickle-cell-disease 2024-10-28T13:07:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-and017-for-the-treatment-of-sickle-cell-disease 2024-10-28T13:07:45+00:00 weekly 0.7 https://trial.medpath.com/news/dr-reddy-s-launches-medication-to-treat-chronic-constipation-the-week 2024-10-28T13:05:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-reddy-s-launches-medication-to-treat-chronic-constipation-the-week 2024-10-28T13:05:06+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-s-darzalex-regimen-approved-by-ec-for-newly-diagnosed-multiple-myeloma-pmlive 2024-10-28T13:04:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/j-j-s-darzalex-regimen-approved-by-ec-for-newly-diagnosed-multiple-myeloma-pmlive 2024-10-28T13:04:02+00:00 weekly 0.7 https://trial.medpath.com/news/ctdna-generates-momentum-in-adjuvant-stage-ii-iii-colon-cancer-setting-onclive 2024-10-28T13:02:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ctdna-generates-momentum-in-adjuvant-stage-ii-iii-colon-cancer-setting-onclive 2024-10-28T13:02:35+00:00 weekly 0.7 https://trial.medpath.com/news/haystack-project-working-with-lawmakers-on-rare-disease-approval-legislation 2024-10-28T13:00:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/haystack-project-working-with-lawmakers-on-rare-disease-approval-legislation 2024-10-28T13:00:44+00:00 weekly 0.7 https://trial.medpath.com/news/neurosense-secures-key-fda-meeting-to-advance-its-phase-3-als-trial-and-nda-submission 2024-10-28T12:59:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurosense-secures-key-fda-meeting-to-advance-its-phase-3-als-trial-and-nda-submission 2024-10-28T12:59:25+00:00 weekly 0.7 https://trial.medpath.com/news/inhaled-reliever-therapies-for-asthma-a-systematic-review-and-meta-analysis 2024-10-28T12:58:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inhaled-reliever-therapies-for-asthma-a-systematic-review-and-meta-analysis 2024-10-28T12:58:26+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-iterum-s-orlynvah-nda-for-uuti-treatment-pharmaceutical-technology 2024-10-28T12:51:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-iterum-s-orlynvah-nda-for-uuti-treatment-pharmaceutical-technology 2024-10-28T12:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-iterum-s-orlynvah-for-urinary-tract-infection-world-pharmaceutical-frontiers 2024-10-28T12:46:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-iterum-s-orlynvah-for-urinary-tract-infection-world-pharmaceutical-frontiers 2024-10-28T12:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/poltreg-launches-phase-2-cell-therapy-trial-in-children-with-presymptomatic-diabetes 2024-10-28T12:35:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poltreg-launches-phase-2-cell-therapy-trial-in-children-with-presymptomatic-diabetes 2024-10-28T12:35:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-uti-drug-for-women-who-have-run-out-of-options-kff-health-news 2024-10-28T12:35:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-uti-drug-for-women-who-have-run-out-of-options-kff-health-news 2024-10-28T12:35:03+00:00 weekly 0.7 https://trial.medpath.com/news/rejuvenate-biomed-partners-with-nihr-leicester-brc-for-phase-2-trial-of-novel-copd-related-sarcopenia-treatment 2024-10-28T12:33:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rejuvenate-biomed-partners-with-nihr-leicester-brc-for-phase-2-trial-of-novel-copd-related-sarcopenia-treatment 2024-10-28T12:33:22+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-dual-energy-system-for-af-ablation-tctmd-com 2024-10-28T12:30:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-dual-energy-system-for-af-ablation-tctmd-com 2024-10-28T12:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-research-uk-kisoji-biotechnology-collaborate-to-advance-the-first-naked-antibody 2024-10-28T12:29:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cancer-research-uk-kisoji-biotechnology-collaborate-to-advance-the-first-naked-antibody 2024-10-28T12:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/recce-pharmaceuticals-receives-interim-efficacy-data-and-safety-approval-to-continue 2024-10-28T12:29:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recce-pharmaceuticals-receives-interim-efficacy-data-and-safety-approval-to-continue 2024-10-28T12:29:07+00:00 weekly 0.7 https://trial.medpath.com/news/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:26:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:26:39+00:00 weekly 0.7 https://trial.medpath.com/news/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:14:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:14:29+00:00 weekly 0.7 https://trial.medpath.com/news/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:13:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vensica-medical-secures-11m-in-funding-to-support-phase-2-trials-for-overactive-bladder 2024-10-28T12:13:45+00:00 weekly 0.7 https://trial.medpath.com/news/msd-moderna-start-phase-3-adjuvant-lung-cancer-trial-pharmaphorum 2024-10-28T12:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/msd-moderna-start-phase-3-adjuvant-lung-cancer-trial-pharmaphorum 2024-10-28T12:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/radium-223-and-enzalutamide-game-changing-peace-iii-phase-3-data-in-mcrpc 2024-10-28T12:07:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radium-223-and-enzalutamide-game-changing-peace-iii-phase-3-data-in-mcrpc 2024-10-28T12:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-inc-to-host-webinar-on-cognitive-testing-using-emacc-and-cdr-sb 2024-10-28T12:05:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-inc-to-host-webinar-on-cognitive-testing-using-emacc-and-cdr-sb 2024-10-28T12:05:18+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-wins-fda-approval-for-oral-uti-antibiotic-seeks-strategic-transaction-for-asset 2024-10-28T12:02:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-wins-fda-approval-for-oral-uti-antibiotic-seeks-strategic-transaction-for-asset 2024-10-28T12:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/biosenic-provides-third-quarter-2024-business-update-globenewswire 2024-10-28T12:02:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosenic-provides-third-quarter-2024-business-update-globenewswire 2024-10-28T12:02:38+00:00 weekly 0.7 https://trial.medpath.com/news/validation-and-refinement-of-the-2022-european-leukaemianet-genetic-risk-classification-nature 2024-10-28T11:58:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/validation-and-refinement-of-the-2022-european-leukaemianet-genetic-risk-classification-nature 2024-10-28T11:58:07+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved-stock-titan 2024-10-28T11:58:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved-stock-titan 2024-10-28T11:58:01+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-announces-presentation-of-positive-results-from-v007-phase-3-av-access 2024-10-28T11:45:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-announces-presentation-of-positive-results-from-v007-phase-3-av-access 2024-10-28T11:45:50+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-biospace 2024-10-28T11:42:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-biospace 2024-10-28T11:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved 2024-10-28T11:35:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-ketamir-2-shows-60-greater-efficacy-than-fda-approved 2024-10-28T11:35:59+00:00 weekly 0.7 https://trial.medpath.com/news/t-neuro-pharma-to-presents-expanded-alzheimer-s-disease-blood-biomarker-assay-at 2024-10-28T11:29:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t-neuro-pharma-to-presents-expanded-alzheimer-s-disease-blood-biomarker-assay-at 2024-10-28T11:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-morningstar 2024-10-28T11:21:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-in-morningstar 2024-10-28T11:21:41+00:00 weekly 0.7 https://trial.medpath.com/news/delta-fly-pharma-inc-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml-patients 2024-10-28T11:21:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/delta-fly-pharma-inc-phase-i-ii-study-of-dfp-10917-and-venetoclax-in-aml-patients 2024-10-28T11:21:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-tyra-biosciences-trial-for-dwarfism-drug-investing-com 2024-10-28T11:14:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-tyra-biosciences-trial-for-dwarfism-drug-investing-com 2024-10-28T11:14:22+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-announces-presentation-of-positive-results-from-v007-phase-3-av-access-stock-titan 2024-10-28T11:13:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/humacyte-announces-presentation-of-positive-results-from-v007-phase-3-av-access-stock-titan 2024-10-28T11:13:20+00:00 weekly 0.7 https://trial.medpath.com/news/tyra-biosciences-receives-ind-clearance-from-fda-to-proceed-with-phase-2-study-stock-titan 2024-10-28T11:13:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tyra-biosciences-receives-ind-clearance-from-fda-to-proceed-with-phase-2-study-stock-titan 2024-10-28T11:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/eyepoint-pharmaceuticals-announces-positive-interim-16-week-globenewswire 2024-10-28T11:05:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyepoint-pharmaceuticals-announces-positive-interim-16-week-globenewswire 2024-10-28T11:05:40+00:00 weekly 0.7 https://trial.medpath.com/news/a-digital-decentralized-trial-of-exercise-therapy-in-patients-with-cancer-nature 2024-10-28T11:04:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-digital-decentralized-trial-of-exercise-therapy-in-patients-with-cancer-nature 2024-10-28T11:04:49+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-to-present-new-clinical-and-health-economics-and-outcomes 2024-10-28T11:04:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-to-present-new-clinical-and-health-economics-and-outcomes 2024-10-28T11:04:22+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-yahoo-finance 2024-10-28T10:53:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-moderna-initiate-phase-3-trial-evaluating-adjuvant-v940-mrna-4157-yahoo-finance 2024-10-28T10:53:05+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-clinical-showcase-highlighting-progress-in-retinal-gene-therapy-clinical-trials-in 2024-10-28T10:47:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-clinical-showcase-highlighting-progress-in-retinal-gene-therapy-clinical-trials-in 2024-10-28T10:47:03+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-to-present-phase-ii-data-at-acr-convergence-2024-biospace 2024-10-28T10:44:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/levicept-to-present-phase-ii-data-at-acr-convergence-2024-biospace 2024-10-28T10:44:36+00:00 weekly 0.7 https://trial.medpath.com/news/aravax-completes-recruitment-into-phase-2-study-of-pvx108-a-novel-immunotherapy-for 2024-10-28T10:44:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aravax-completes-recruitment-into-phase-2-study-of-pvx108-a-novel-immunotherapy-for 2024-10-28T10:44:35+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-gets-nod-to-launch-blockbuster-weight-loss-drug-in-hong-kong-medwatch 2024-10-28T10:42:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-gets-nod-to-launch-blockbuster-weight-loss-drug-in-hong-kong-medwatch 2024-10-28T10:42:42+00:00 weekly 0.7 https://trial.medpath.com/news/sebetralstat-shows-promise-in-phase-3-hae-trial-investing-com 2024-10-28T10:42:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sebetralstat-shows-promise-in-phase-3-hae-trial-investing-com 2024-10-28T10:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-pulls-geographic-atrophy-drug-filing-in-the-eu-pharmaphorum 2024-10-28T10:36:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astellas-pulls-geographic-atrophy-drug-filing-in-the-eu-pharmaphorum 2024-10-28T10:36:15+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-or-mounjaro-the-battle-of-the-weight-loss-injections-evening-standard 2024-10-28T10:35:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-wegovy-or-mounjaro-the-battle-of-the-weight-loss-injections-evening-standard 2024-10-28T10:35:38+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-clinical-showcase-highlighting-progress-in-retinal-globenewswire 2024-10-28T10:33:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-clinical-showcase-highlighting-progress-in-retinal-globenewswire 2024-10-28T10:33:56+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-biosciences-announces-ind-clearance-for-werner-helicase-development-pr-newswire 2024-10-28T10:22:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-biosciences-announces-ind-clearance-for-werner-helicase-development-pr-newswire 2024-10-28T10:22:48+00:00 weekly 0.7 https://trial.medpath.com/news/brainstorm-cell-therapeutics-presented-positive-survival-data-from-nurown-r-expanded 2024-10-28T10:15:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brainstorm-cell-therapeutics-presented-positive-survival-data-from-nurown-r-expanded 2024-10-28T10:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-fabhalta-shows-positive-outcomes-in-c3-glomerulopathy-treatment 2024-10-28T10:11:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-fabhalta-shows-positive-outcomes-in-c3-glomerulopathy-treatment 2024-10-28T10:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/skin-patch-uses-imperceptible-electric-zaps-to-heal-wounds-without-drugs 2024-10-28T10:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skin-patch-uses-imperceptible-electric-zaps-to-heal-wounds-without-drugs 2024-10-28T10:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/new-hope-against-a-rare-aggressive-form-of-thyroid-cancer 2024-10-28T10:10:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-hope-against-a-rare-aggressive-form-of-thyroid-cancer 2024-10-28T10:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-curbs-kidney-disease-in-obese-people-without-diabetes 2024-10-28T10:10:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-curbs-kidney-disease-in-obese-people-without-diabetes 2024-10-28T10:10:05+00:00 weekly 0.7 https://trial.medpath.com/news/legislation-will-allow-wvu-researcher-to-study-buprenorphine-at-new-martinsville-clinic 2024-10-28T10:07:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/legislation-will-allow-wvu-researcher-to-study-buprenorphine-at-new-martinsville-clinic 2024-10-28T10:07:53+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-withdraws-europe-acp-application-for-amd-treatment-pharmaceutical-technology 2024-10-28T09:52:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astellas-withdraws-europe-acp-application-for-amd-treatment-pharmaceutical-technology 2024-10-28T09:52:12+00:00 weekly 0.7 https://trial.medpath.com/news/levicept-to-present-phase-ii-data-at-acr-convergence-2024-morningstar 2024-10-28T09:48:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/levicept-to-present-phase-ii-data-at-acr-convergence-2024-morningstar 2024-10-28T09:48:51+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-weight-loss-drug-mounjaro-set-for-hong-kong-launch-report-investing-com-uk 2024-10-28T09:38:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-weight-loss-drug-mounjaro-set-for-hong-kong-launch-report-investing-com-uk 2024-10-28T09:38:13+00:00 weekly 0.7 https://trial.medpath.com/news/fostering-regulatory-collaboration-to-improve-access-to-mpox-medicines-pharmabiz 2024-10-28T09:30:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fostering-regulatory-collaboration-to-improve-access-to-mpox-medicines-pharmabiz 2024-10-28T09:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/aravax-completes-recruitment-into-phase-2-study-of-pvx108-a-novel-immunotherapy-for 2024-10-28T09:21:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aravax-completes-recruitment-into-phase-2-study-of-pvx108-a-novel-immunotherapy-for 2024-10-28T09:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T09:08:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-to-host-morning-conference-call-on-u-s-fda-approval-of-orlynvah 2024-10-28T09:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/ideaya-reports-positive-interim-phase-1-expansion-data-of-ide397-in-mtap-deletion-pharmabiz 2024-10-28T08:30:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideaya-reports-positive-interim-phase-1-expansion-data-of-ide397-in-mtap-deletion-pharmabiz 2024-10-28T08:30:25+00:00 weekly 0.7 https://trial.medpath.com/news/dtab-recommends-amendment-of-mdr-2017-to-include-eu-under-rule-63-pharmabiz 2024-10-28T08:29:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dtab-recommends-amendment-of-mdr-2017-to-include-eu-under-rule-63-pharmabiz 2024-10-28T08:29:41+00:00 weekly 0.7 https://trial.medpath.com/news/yuhan-s-q3-operating-profit-surges-690-on-us-sale-of-lung-cancer-drug-lazertinib-kbr 2024-10-28T07:49:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yuhan-s-q3-operating-profit-surges-690-on-us-sale-of-lung-cancer-drug-lazertinib-kbr 2024-10-28T07:49:14+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T07:09:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T07:09:36+00:00 weekly 0.7 https://trial.medpath.com/news/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis-astrazeneca 2024-10-28T07:04:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fasenra-approved-in-the-eu-for-eosinophilic-granulomatosis-with-polyangiitis-astrazeneca 2024-10-28T07:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/automatic-setting-optimization-for-robotic-upper-extremity-rehabilitation-in-patients-with-nature 2024-10-28T06:58:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/automatic-setting-optimization-for-robotic-upper-extremity-rehabilitation-in-patients-with-nature 2024-10-28T06:58:31+00:00 weekly 0.7 https://trial.medpath.com/news/a-real-world-pharmacovigilance-study-of-fda-adverse-event-reporting-system-events-for 2024-10-28T06:48:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-real-world-pharmacovigilance-study-of-fda-adverse-event-reporting-system-events-for 2024-10-28T06:48:31+00:00 weekly 0.7 https://trial.medpath.com/news/global-tb-crisis-persists-chest-2024-leaders-highlight-post-covid-challenges-and-rising-death-toll 2024-10-28T06:13:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-tb-crisis-persists-chest-2024-leaders-highlight-post-covid-challenges-and-rising-death-toll 2024-10-28T06:13:24+00:00 weekly 0.7 https://trial.medpath.com/news/vanderbilt-health-study-specialty-pharmacists-drive-significant-cost-savings-in-high-cost-medication-management 2024-10-28T05:52:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vanderbilt-health-study-specialty-pharmacists-drive-significant-cost-savings-in-high-cost-medication-management 2024-10-28T05:52:21+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-presents-lomecel-btm-long-term-transplant-free-survival-data-in-biospace 2024-10-28T05:51:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-presents-lomecel-btm-long-term-transplant-free-survival-data-in-biospace 2024-10-28T05:51:03+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-trial-assesses-clazakizumab-in-kidney-transplant-recipients-with-caamr 2024-10-28T05:43:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-trial-assesses-clazakizumab-in-kidney-transplant-recipients-with-caamr 2024-10-28T05:43:19+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-reports-positive-phase-3-results-for-lnz100-in-presbyopia-trial-in-china 2024-10-28T05:32:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenz-therapeutics-reports-positive-phase-3-results-for-lnz100-in-presbyopia-trial-in-china 2024-10-28T05:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/nih-clinical-trial-will-test-precision-medicine-treatments-for-myeloid-cancers 2024-10-28T05:30:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-clinical-trial-will-test-precision-medicine-treatments-for-myeloid-cancers 2024-10-28T05:30:13+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-s-phase-3-trial-confirms-yuflyma-s-interchangeability-with-humira-kbr 2024-10-28T05:01:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celltrion-s-phase-3-trial-confirms-yuflyma-s-interchangeability-with-humira-kbr 2024-10-28T05:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/development-of-a-prognosis-prediction-model-for-pediatric-sepsis-based-jir 2024-10-28T04:58:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/development-of-a-prognosis-prediction-model-for-pediatric-sepsis-based-jir 2024-10-28T04:58:34+00:00 weekly 0.7 https://trial.medpath.com/news/dimerix-announces-key-developments-in-kidney-disease-trials-markets-insider 2024-10-28T04:12:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dimerix-announces-key-developments-in-kidney-disease-trials-markets-insider 2024-10-28T04:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/eu-advances-critical-medicines-act-to-reduce-asian-supply-chain-dependence 2024-10-28T04:11:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eu-advances-critical-medicines-act-to-reduce-asian-supply-chain-dependence 2024-10-28T04:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/sarepta-s-recent-elevidys-presentations-leave-duchenne-community-wanting-biospace 2024-10-28T04:07:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sarepta-s-recent-elevidys-presentations-leave-duchenne-community-wanting-biospace 2024-10-28T04:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/evolving-fda-accelerated-approval-pathway-suffers-spate-of-withdrawals-biospace 2024-10-28T04:07:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolving-fda-accelerated-approval-pathway-suffers-spate-of-withdrawals-biospace 2024-10-28T04:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/opinion-new-therapies-are-set-to-upend-treatment-of-genetic-disorder-aatd-biospace 2024-10-28T04:06:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opinion-new-therapies-are-set-to-upend-treatment-of-genetic-disorder-aatd-biospace 2024-10-28T04:06:51+00:00 weekly 0.7 https://trial.medpath.com/news/rising-gynecological-cancer-cases-prompt-push-for-enhanced-research-and-awareness 2024-10-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rising-gynecological-cancer-cases-prompt-push-for-enhanced-research-and-awareness 2024-10-28T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nihr-to-launch-new-ps15-million-funding-for-uk-australia-clinical-trials-pharmabiz 2024-10-28T03:29:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nihr-to-launch-new-ps15-million-funding-for-uk-australia-clinical-trials-pharmabiz 2024-10-28T03:29:15+00:00 weekly 0.7 https://trial.medpath.com/news/astragalus-polysaccharides-improve-adjuvant-chemotherapy-induced-fatigue-for-patients 2024-10-28T03:15:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astragalus-polysaccharides-improve-adjuvant-chemotherapy-induced-fatigue-for-patients 2024-10-28T03:15:29+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-pharma-withdraws-eu-application-for-key-drug-markets-insider 2024-10-28T03:09:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astellas-pharma-withdraws-eu-application-for-key-drug-markets-insider 2024-10-28T03:09:58+00:00 weekly 0.7 https://trial.medpath.com/news/dimerix-limited-announces-update-on-parasol-scientific-workshop-marketscreener 2024-10-28T03:07:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dimerix-limited-announces-update-on-parasol-scientific-workshop-marketscreener 2024-10-28T03:07:21+00:00 weekly 0.7 https://trial.medpath.com/news/former-seagen-ceo-leads-ottimo-pharma-s-novel-cancer-immunotherapy-development 2024-10-28T02:52:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/former-seagen-ceo-leads-ottimo-pharma-s-novel-cancer-immunotherapy-development 2024-10-28T02:52:00+00:00 weekly 0.7 https://trial.medpath.com/news/social-media-emerges-as-powerful-tool-for-rare-disease-trial-recruitment-reports-40-response-rate 2024-10-28T02:45:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/social-media-emerges-as-powerful-tool-for-rare-disease-trial-recruitment-reports-40-response-rate 2024-10-28T02:45:25+00:00 weekly 0.7 https://trial.medpath.com/news/a-syk-inhibitor-for-the-treatment-of-autoimmune-disorders 2024-10-28T02:35:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-syk-inhibitor-for-the-treatment-of-autoimmune-disorders 2024-10-28T02:35:47+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news-tradingview 2024-10-28T02:33:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news-tradingview 2024-10-28T02:33:12+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T02:29:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T02:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news-kfgo 2024-10-28T02:10:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news-kfgo 2024-10-28T02:10:01+00:00 weekly 0.7 https://trial.medpath.com/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3 2024-10-28T02:05:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-from-china-phase-3 2024-10-28T02:05:48+00:00 weekly 0.7 https://trial.medpath.com/news/timothy-ritter-md-real-world-data-supporting-fecal-microbiota-for-recurrent-c-diff 2024-10-28T01:32:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/timothy-ritter-md-real-world-data-supporting-fecal-microbiota-for-recurrent-c-diff 2024-10-28T01:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-announces-device-trial-participation-snapshots-food-drugs-healthcare-life-sciences 2024-10-28T01:20:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-announces-device-trial-participation-snapshots-food-drugs-healthcare-life-sciences 2024-10-28T01:20:34+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-sintilimab-and-neoadjuvant-anlotinib-plus-chemotherapy-for-resectable-non-nature 2024-10-28T01:20:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-sintilimab-and-neoadjuvant-anlotinib-plus-chemotherapy-for-resectable-non-nature 2024-10-28T01:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T01:17:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T01:17:17+00:00 weekly 0.7 https://trial.medpath.com/news/day-4-recap-fall-clinical-2024-dermatology-times 2024-10-28T01:12:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/day-4-recap-fall-clinical-2024-dermatology-times 2024-10-28T01:12:38+00:00 weekly 0.7 https://trial.medpath.com/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-globenewswire 2024-10-28T01:11:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/corxel-and-lenz-therapeutics-announce-positive-topline-data-globenewswire 2024-10-28T01:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T01:07:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-gets-nod-to-launch-weight-loss-drug-in-hong-kong-bloomberg-news 2024-10-28T01:07:24+00:00 weekly 0.7 https://trial.medpath.com/news/zegocractin-significantly-improves-acute-pancreatitis-symptoms-in-phase-2-carpo 2024-10-28T01:03:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zegocractin-significantly-improves-acute-pancreatitis-symptoms-in-phase-2-carpo 2024-10-28T01:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-presents-12-month-data-from-the-phase-iii-appear-c3g-study-markets-insider 2024-10-28T00:15:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-presents-12-month-data-from-the-phase-iii-appear-c3g-study-markets-insider 2024-10-28T00:15:03+00:00 weekly 0.7 https://trial.medpath.com/news/infliximab-improves-ulcerative-colitis-crohn-s-disease-regardless-of-immunosuppressants 2024-10-28T00:01:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/infliximab-improves-ulcerative-colitis-crohn-s-disease-regardless-of-immunosuppressants 2024-10-28T00:01:30+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-highlights-efficacy-of-imlifidase-for-kidney-transplant-recipients-news-medical 2024-10-27T23:54:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-highlights-efficacy-of-imlifidase-for-kidney-transplant-recipients-news-medical 2024-10-27T23:54:44+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-pharma-withdraws-eu-application-for-key-drug-tipranks-com 2024-10-27T23:28:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astellas-pharma-withdraws-eu-application-for-key-drug-tipranks-com 2024-10-27T23:28:06+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacovigilance-of-drug-drug-interactions-with-nirmatrelvir-ritonavir-springer-medizin 2024-10-27T23:21:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacovigilance-of-drug-drug-interactions-with-nirmatrelvir-ritonavir-springer-medizin 2024-10-27T23:21:27+00:00 weekly 0.7 https://trial.medpath.com/news/dupilumab-proves-effective-in-chronic-spontaneous-urticaria-medpage-today 2024-10-27T23:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupilumab-proves-effective-in-chronic-spontaneous-urticaria-medpage-today 2024-10-27T23:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/novel-drug-leads-to-responses-in-waldenstrom-macroglobulinemia-oncology-nursing-news 2024-10-27T23:07:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-drug-leads-to-responses-in-waldenstrom-macroglobulinemia-oncology-nursing-news 2024-10-27T23:07:03+00:00 weekly 0.7 https://trial.medpath.com/news/interim-align-data-atrasentan-cuts-proteinuria-in-iga-nephropathy-medpage-today 2024-10-27T22:17:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/interim-align-data-atrasentan-cuts-proteinuria-in-iga-nephropathy-medpage-today 2024-10-27T22:17:23+00:00 weekly 0.7 https://trial.medpath.com/news/exact-sciences-presents-multiple-studies-at-acg-2024-demonstrating-leadership-in-quantisnow 2024-10-27T22:17:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exact-sciences-presents-multiple-studies-at-acg-2024-demonstrating-leadership-in-quantisnow 2024-10-27T22:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-american-college-of-quantisnow 2024-10-27T22:17:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-american-college-of-quantisnow 2024-10-27T22:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/can-merrimack-get-a-high-five 2024-10-27T21:49:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-merrimack-get-a-high-five 2024-10-27T21:49:11+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-shows-promise-against-alzheimer-s-disease-the-pinnacle-gazette 2024-10-27T21:03:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-shows-promise-against-alzheimer-s-disease-the-pinnacle-gazette 2024-10-27T21:03:24+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-presents-12-month-data-from-the-phase-iii-appear-c3g-study-tipranks-com 2024-10-27T20:21:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-presents-12-month-data-from-the-phase-iii-appear-c3g-study-tipranks-com 2024-10-27T20:21:22+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-comparable-efficacy-of-clascoterone-trifarotene-and-tazarotene-in-acne-treatment 2024-10-27T20:07:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-comparable-efficacy-of-clascoterone-trifarotene-and-tazarotene-in-acne-treatment 2024-10-27T20:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/patient-reported-outcomes-for-roflumilast-foam-highlighted-for-seborrheic-dermatitis 2024-10-27T19:33:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patient-reported-outcomes-for-roflumilast-foam-highlighted-for-seborrheic-dermatitis 2024-10-27T19:33:52+00:00 weekly 0.7 https://trial.medpath.com/news/origin-ole-data-solidify-atacicept-disease-modifying-potential-for-iga-nephropathy 2024-10-27T19:32:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/origin-ole-data-solidify-atacicept-disease-modifying-potential-for-iga-nephropathy 2024-10-27T19:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-highlight-long-term-benefits-of-heartflow-s-ai-based-cad-evaluations 2024-10-27T19:32:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-highlight-long-term-benefits-of-heartflow-s-ai-based-cad-evaluations 2024-10-27T19:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-presents-lomecel-btm-long-term-transplant-free-globenewswire 2024-10-27T19:21:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-presents-lomecel-btm-long-term-transplant-free-globenewswire 2024-10-27T19:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-presents-positive-results-from-phase-2-ignaz-study-of-felzartamab-in-iga-stock-titan 2024-10-27T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-presents-positive-results-from-phase-2-ignaz-study-of-felzartamab-in-iga-stock-titan 2024-10-27T18:50:41+00:00 weekly 0.7 https://trial.medpath.com/news/emmy-graber-mb-mba-shares-top-clinical-pearls-on-lasers-erythema-treatments-and 2024-10-27T17:12:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emmy-graber-mb-mba-shares-top-clinical-pearls-on-lasers-erythema-treatments-and 2024-10-27T17:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/unpack-the-latest-fda-approvals-and-updates-including-a-new-dosage-for-her2-cancers 2024-10-27T17:01:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unpack-the-latest-fda-approvals-and-updates-including-a-new-dosage-for-her2-cancers 2024-10-27T17:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/transcatheter-arterial-chemoembolization-plus-sorafenib-versus-transcatheter-arterial-nature 2024-10-27T16:58:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transcatheter-arterial-chemoembolization-plus-sorafenib-versus-transcatheter-arterial-nature 2024-10-27T16:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-american-college-of-morningstar 2024-10-27T16:54:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-american-college-of-morningstar 2024-10-27T16:54:45+00:00 weekly 0.7 https://trial.medpath.com/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-27T16:45:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-27T16:45:40+00:00 weekly 0.7 https://trial.medpath.com/news/acg-presidential-plenary-to-highlight-analysis-of-xifaxan-r-rifaximin-risk-reduction-of 2024-10-27T16:30:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acg-presidential-plenary-to-highlight-analysis-of-xifaxan-r-rifaximin-risk-reduction-of 2024-10-27T16:30:54+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-compass-semaglutide-for-nondiabetic-kidney-disease-with-hiddo-heerspink-phd 2024-10-27T16:20:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-compass-semaglutide-for-nondiabetic-kidney-disease-with-hiddo-heerspink-phd 2024-10-27T16:20:05+00:00 weekly 0.7 https://trial.medpath.com/news/painkiller-taken-by-millions-could-raise-risk-of-heart-attack-by-50-per-cent-warns-study 2024-10-27T16:18:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/painkiller-taken-by-millions-could-raise-risk-of-heart-attack-by-50-per-cent-warns-study 2024-10-27T16:18:53+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-sobi-announced-results-from-phase-3-valiant-study-markets-insider 2024-10-27T16:15:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apellis-sobi-announced-results-from-phase-3-valiant-study-markets-insider 2024-10-27T16:15:56+00:00 weekly 0.7 https://trial.medpath.com/news/nonopioid-medication-overuse-headache-remission-observed-with-erenumab 2024-10-27T16:12:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nonopioid-medication-overuse-headache-remission-observed-with-erenumab 2024-10-27T16:12:17+00:00 weekly 0.7 https://trial.medpath.com/news/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-globenewswire 2024-10-27T16:11:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phathom-pharmaceuticals-to-present-voquezna-r-data-at-the-globenewswire 2024-10-27T16:11:28+00:00 weekly 0.7 https://trial.medpath.com/news/could-buying-this-weight-loss-stock-be-like-investing-in-novo-nordisk-at-the-dawn-of-the 2024-10-27T15:48:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-buying-this-weight-loss-stock-be-like-investing-in-novo-nordisk-at-the-dawn-of-the 2024-10-27T15:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/positive-trial-results-for-pyc-s-eye-disease-therapies-sharecafe 2024-10-27T15:26:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-trial-results-for-pyc-s-eye-disease-therapies-sharecafe 2024-10-27T15:26:22+00:00 weekly 0.7 https://trial.medpath.com/news/could-buying-this-weight-loss-stock-be-like-investing-in-novo-nordisk-at-the-dawn-of-the 2024-10-27T15:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-buying-this-weight-loss-stock-be-like-investing-in-novo-nordisk-at-the-dawn-of-the 2024-10-27T15:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-shows-felzartamab-reduces-proteinuria-in-iga-nephropathy-patients 2024-10-27T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trial-shows-felzartamab-reduces-proteinuria-in-iga-nephropathy-patients 2024-10-27T14:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/weekend-icymi-october-21-to-october-25-drug-topics 2024-10-27T14:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekend-icymi-october-21-to-october-25-drug-topics 2024-10-27T14:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/what-experts-say-about-taking-psilocybin-as-an-alternative-treatment-for-depression-wxow 2024-10-27T14:04:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-experts-say-about-taking-psilocybin-as-an-alternative-treatment-for-depression-wxow 2024-10-27T14:04:44+00:00 weekly 0.7 https://trial.medpath.com/news/catalyst-orthoscience-receives-fda-510-k-clearance-of-proximal-humerus-fracture-system 2024-10-27T14:03:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/catalyst-orthoscience-receives-fda-510-k-clearance-of-proximal-humerus-fracture-system 2024-10-27T14:03:18+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T13:59:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T13:59:59+00:00 weekly 0.7 https://trial.medpath.com/news/carla-nester-md-pegcetacoplan-in-c3-glomerulopathy-and-primary-ic-mpgn-hcplive 2024-10-27T13:30:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carla-nester-md-pegcetacoplan-in-c3-glomerulopathy-and-primary-ic-mpgn-hcplive 2024-10-27T13:30:52+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-announces-promising-12-month-results-for-fabhalta-in-c3-glomerulopathy 2024-10-27T13:25:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-announces-promising-12-month-results-for-fabhalta-in-c3-glomerulopathy 2024-10-27T13:25:40+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-announces-promising-12-month-results-for-fabhalta-in-c3-glomerulopathy 2024-10-27T13:17:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-announces-promising-12-month-results-for-fabhalta-in-c3-glomerulopathy 2024-10-27T13:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/jspr-jasper-therapeutics-inc-latest-stock-news-market-updates 2024-10-27T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jspr-jasper-therapeutics-inc-latest-stock-news-market-updates 2024-10-27T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/with-92m-kivu-sets-out-to-make-kinder-gentler-adcs-biopharma-dive 2024-10-27T12:46:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-92m-kivu-sets-out-to-make-kinder-gentler-adcs-biopharma-dive 2024-10-27T12:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-sobi-announced-results-from-phase-3-valiant-study-tipranks-com 2024-10-27T12:43:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apellis-sobi-announced-results-from-phase-3-valiant-study-tipranks-com 2024-10-27T12:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-presents-positive-results-from-phase-2-ignaz-study-of-felzartamab-in-iga-quantisnow 2024-10-27T12:31:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-presents-positive-results-from-phase-2-ignaz-study-of-felzartamab-in-iga-quantisnow 2024-10-27T12:31:52+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-announces-96-week-egfr-stabilization-in-globenewswire 2024-10-27T11:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-announces-96-week-egfr-stabilization-in-globenewswire 2024-10-27T11:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-semaglutide-may-reduce-kidney-damage-study-finds-the-express-tribune 2024-10-27T11:20:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diabetes-drug-semaglutide-may-reduce-kidney-damage-study-finds-the-express-tribune 2024-10-27T11:20:49+00:00 weekly 0.7 https://trial.medpath.com/news/a-multipronged-approach-can-address-disparities-in-cancer-care-for-patients-in-rural-communities 2024-10-27T11:19:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-multipronged-approach-can-address-disparities-in-cancer-care-for-patients-in-rural-communities 2024-10-27T11:19:31+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T10:26:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T10:26:32+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of 2024-10-27T10:20:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of 2024-10-27T10:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high-statistical 2024-10-27T10:13:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high-statistical 2024-10-27T10:13:02+00:00 weekly 0.7 https://trial.medpath.com/news/dr-panken-discusses-study-evaluating-trt-and-atrial-fibrillation-acute-kidney-injury 2024-10-27T10:01:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-panken-discusses-study-evaluating-trt-and-atrial-fibrillation-acute-kidney-injury 2024-10-27T10:01:56+00:00 weekly 0.7 https://trial.medpath.com/news/uconn-professors-are-working-to-treat-pain-without-opioids-shelton-herald 2024-10-27T09:12:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uconn-professors-are-working-to-treat-pain-without-opioids-shelton-herald 2024-10-27T09:12:09+00:00 weekly 0.7 https://trial.medpath.com/news/arovella-receives-r-d-tax-incentive-and-new-advisory-board-finance-news-network 2024-10-27T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arovella-receives-r-d-tax-incentive-and-new-advisory-board-finance-news-network 2024-10-27T08:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/rocatinlimab-improves-scorad-in-adults-with-moderate-to-severe-ad 2024-10-27T08:43:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rocatinlimab-improves-scorad-in-adults-with-moderate-to-severe-ad 2024-10-27T08:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-results-demonstrate-clinically-meaningful-improvements-in-hair-regrowth 2024-10-27T08:43:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-results-demonstrate-clinically-meaningful-improvements-in-hair-regrowth 2024-10-27T08:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/pressr-kfshrc-advances-clinical-trials-through-strategic-partnerships-tradingview 2024-10-27T08:27:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pressr-kfshrc-advances-clinical-trials-through-strategic-partnerships-tradingview 2024-10-27T08:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/echo-iq-secures-fda-clearance-for-ai-software-finance-news-network 2024-10-27T07:46:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/echo-iq-secures-fda-clearance-for-ai-software-finance-news-network 2024-10-27T07:46:59+00:00 weekly 0.7 https://trial.medpath.com/news/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-2 2024-10-27T07:35:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-2 2024-10-27T07:35:12+00:00 weekly 0.7 https://trial.medpath.com/news/trial-assesses-antibody-therapy-for-chronic-a-eurekalert 2024-10-27T07:35:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-assesses-antibody-therapy-for-chronic-a-eurekalert 2024-10-27T07:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-27T06:22:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-27T06:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-shows-benefit-in-ckd-and-type-2-diabetes-across-kidney-disease-severities 2024-10-27T06:20:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-shows-benefit-in-ckd-and-type-2-diabetes-across-kidney-disease-severities 2024-10-27T06:20:02+00:00 weekly 0.7 https://trial.medpath.com/news/valiant-pegcetacoplan-offers-benefit-for-upcr-egfr-c3-staining-in-c3g-ic-mpgn 2024-10-27T06:03:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valiant-pegcetacoplan-offers-benefit-for-upcr-egfr-c3-staining-in-c3g-ic-mpgn 2024-10-27T06:03:05+00:00 weekly 0.7 https://trial.medpath.com/news/pbm-payment-disparities-threaten-independent-pharmacies-chain-stores-receive-up-to-15x-higher-reimbursements 2024-10-27T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pbm-payment-disparities-threaten-independent-pharmacies-chain-stores-receive-up-to-15x-higher-reimbursements 2024-10-27T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T05:54:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T05:54:22+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-globenewswire 2024-10-27T05:51:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-globenewswire 2024-10-27T05:51:31+00:00 weekly 0.7 https://trial.medpath.com/news/adcs-may-change-the-landscape-of-her2-mutant-nsclc-oncology-nursing-news 2024-10-27T05:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adcs-may-change-the-landscape-of-her2-mutant-nsclc-oncology-nursing-news 2024-10-27T05:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-inc-latest-stock-news-market-updates 2024-10-27T04:47:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-inc-latest-stock-news-market-updates 2024-10-27T04:47:13+00:00 weekly 0.7 https://trial.medpath.com/news/depagliflozin-lowers-risk-of-decline-in-late-stage-kidney-disease-hcplive 2024-10-27T04:26:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/depagliflozin-lowers-risk-of-decline-in-late-stage-kidney-disease-hcplive 2024-10-27T04:26:17+00:00 weekly 0.7 https://trial.medpath.com/news/final-ecztend-study-results-confirm-long-term-safety-and-efficacy-of-tralokinumab-for 2024-10-27T04:02:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-ecztend-study-results-confirm-long-term-safety-and-efficacy-of-tralokinumab-for 2024-10-27T04:02:30+00:00 weekly 0.7 https://trial.medpath.com/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-27T04:01:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-27T04:01:51+00:00 weekly 0.7 https://trial.medpath.com/news/apple-s-airpods-as-hearing-aids-a-step-forward-in-hearing-loss-care-but-barriers-remain 2024-10-27T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-s-airpods-as-hearing-aids-a-step-forward-in-hearing-loss-care-but-barriers-remain 2024-10-27T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/investigational-nipocalimab-demonstrates-efficacy-and-safety-in-adolescent-population-of 2024-10-27T03:12:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigational-nipocalimab-demonstrates-efficacy-and-safety-in-adolescent-population-of 2024-10-27T03:12:16+00:00 weekly 0.7 https://trial.medpath.com/news/how-ozempic-could-cure-common-leg-problem-one-in-ten-women-suffer-as-some-say-nhs 2024-10-27T02:36:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/how-ozempic-could-cure-common-leg-problem-one-in-ten-women-suffer-as-some-say-nhs 2024-10-27T02:36:05+00:00 weekly 0.7 https://trial.medpath.com/news/lebrikizumab-demonstrates-efficacy-in-itch-and-skin-clearance-among-patients-with-ad 2024-10-27T02:12:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lebrikizumab-demonstrates-efficacy-in-itch-and-skin-clearance-among-patients-with-ad 2024-10-27T02:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/richard-pratley-md-flow-mortality-data-and-allocation-strategies-for-semaglutide 2024-10-27T01:39:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/richard-pratley-md-flow-mortality-data-and-allocation-strategies-for-semaglutide 2024-10-27T01:39:58+00:00 weekly 0.7 https://trial.medpath.com/news/advanced-nanotherapies-announces-positive-results-in-its-first-in 2024-10-27T01:12:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/advanced-nanotherapies-announces-positive-results-in-its-first-in 2024-10-27T01:12:37+00:00 weekly 0.7 https://trial.medpath.com/news/day-3-recap-fall-clinical-2024-dermatology-times 2024-10-27T01:12:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/day-3-recap-fall-clinical-2024-dermatology-times 2024-10-27T01:12:18+00:00 weekly 0.7 https://trial.medpath.com/news/pediatric-febrile-uti-may-hurt-kidney-function-medpage-today 2024-10-27T01:09:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pediatric-febrile-uti-may-hurt-kidney-function-medpage-today 2024-10-27T01:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T00:55:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T00:55:23+00:00 weekly 0.7 https://trial.medpath.com/news/icu-seastar-medical-holding-corporation-latest-stock-news-market-updates 2024-10-27T00:43:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icu-seastar-medical-holding-corporation-latest-stock-news-market-updates 2024-10-27T00:43:17+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-10-20-onclive 2024-10-27T00:32:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-oncfive-top-oncology-articles-for-the-week-of-10-20-onclive 2024-10-27T00:32:35+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-pharma-ag-globenewswire 2024-10-27T00:31:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-pharma-ag-globenewswire 2024-10-27T00:31:58+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T00:29:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-27T00:29:08+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-compass-atacicept-for-igan-with-jonathan-barratt-phd-at-kidney-week-2024 2024-10-27T00:26:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kidney-compass-atacicept-for-igan-with-jonathan-barratt-phd-at-kidney-week-2024 2024-10-27T00:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of 2024-10-27T00:18:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-announces-96-week-egfr-stabilization-in-origin-phase-2b-study-of 2024-10-27T00:18:37+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-26T23:54:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-oral-fabhalta-r-iptacopan-sustained-clinically-meaningful-results-at-one-year-in 2024-10-26T23:54:33+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-yield-promising-kidney-health-results-mirage-news 2024-10-26T23:33:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-yield-promising-kidney-health-results-mirage-news 2024-10-26T23:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-presents-data-reinforcing-clinical-benefit-of-filspari-r-sparsentan 2024-10-26T23:16:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/travere-therapeutics-presents-data-reinforcing-clinical-benefit-of-filspari-r-sparsentan 2024-10-26T23:16:59+00:00 weekly 0.7 https://trial.medpath.com/news/ribox-therapeutics-announces-fda-clearance-for-ind-application-of-rxrg001-the-first 2024-10-26T23:11:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ribox-therapeutics-announces-fda-clearance-for-ind-application-of-rxrg001-the-first 2024-10-26T23:11:55+00:00 weekly 0.7 https://trial.medpath.com/news/analysis-shows-perioperative-pembrolizumab-efficacy-in-nsclc-targeted-oncology 2024-10-26T23:01:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/analysis-shows-perioperative-pembrolizumab-efficacy-in-nsclc-targeted-oncology 2024-10-26T23:01:47+00:00 weekly 0.7 https://trial.medpath.com/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-26T22:22:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high 2024-10-26T22:22:24+00:00 weekly 0.7 https://trial.medpath.com/news/the-european-medicines-agency-approved-the-first-anti-coronavirus-pill-telegrafi 2024-10-26T22:05:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-european-medicines-agency-approved-the-first-anti-coronavirus-pill-telegrafi 2024-10-26T22:05:02+00:00 weekly 0.7 https://trial.medpath.com/news/alternative-pathway-inhibition-makes-good-in-iga-nephropathy-medpage-today 2024-10-26T21:48:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alternative-pathway-inhibition-makes-good-in-iga-nephropathy-medpage-today 2024-10-26T21:48:39+00:00 weekly 0.7 https://trial.medpath.com/news/celldex-announces-barzolvolimab-met-all-primary-and-globenewswire 2024-10-26T21:46:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celldex-announces-barzolvolimab-met-all-primary-and-globenewswire 2024-10-26T21:46:50+00:00 weekly 0.7 https://trial.medpath.com/news/ringer-s-lactate-administered-at-15-degc-leads-to-a-greater-and-more-prolonged-increase-in 2024-10-26T21:07:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ringer-s-lactate-administered-at-15-degc-leads-to-a-greater-and-more-prolonged-increase-in 2024-10-26T21:07:12+00:00 weekly 0.7 https://trial.medpath.com/news/spyre-therapeutics-catalyst-cascade-on-track-for-late-2024-rttnews 2024-10-26T20:35:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spyre-therapeutics-catalyst-cascade-on-track-for-late-2024-rttnews 2024-10-26T20:35:19+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ribociclib-recognized-as-category-1-preferred-breast-cancer-adjuvant-treatment-by 2024-10-26T20:29:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-ribociclib-recognized-as-category-1-preferred-breast-cancer-adjuvant-treatment-by 2024-10-26T20:29:26+00:00 weekly 0.7 https://trial.medpath.com/news/hope-for-a-revolution-in-treatment-for-severe-burns-victims-sbs-news 2024-10-26T20:20:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hope-for-a-revolution-in-treatment-for-severe-burns-victims-sbs-news 2024-10-26T20:20:39+00:00 weekly 0.7 https://trial.medpath.com/news/5-fluorouracil-combined-with-callisphere-drug-eluting-beads-or-conventional-transarterial-nature 2024-10-26T20:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-fluorouracil-combined-with-callisphere-drug-eluting-beads-or-conventional-transarterial-nature 2024-10-26T20:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-26T19:56:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-26T19:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/patients-taking-ozempic-are-up-to-70-percent-less-likely-to-develop-alzheimer-s-research-finds 2024-10-26T19:36:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patients-taking-ozempic-are-up-to-70-percent-less-likely-to-develop-alzheimer-s-research-finds 2024-10-26T19:36:24+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-linked-to-reduced-albuminuria-for-adults-with-ckd-without-diabetes-healio 2024-10-26T19:21:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-linked-to-reduced-albuminuria-for-adults-with-ckd-without-diabetes-healio 2024-10-26T19:21:01+00:00 weekly 0.7 https://trial.medpath.com/news/efficiency-of-multivariate-tests-in-trials-in-progressive-supranuclear-palsy-nature 2024-10-26T18:36:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficiency-of-multivariate-tests-in-trials-in-progressive-supranuclear-palsy-nature 2024-10-26T18:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/shawn-kwatra-md-making-the-connection-between-prurigo-nodularis-atopic-dermatitis-and-itch 2024-10-26T18:34:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shawn-kwatra-md-making-the-connection-between-prurigo-nodularis-atopic-dermatitis-and-itch 2024-10-26T18:34:50+00:00 weekly 0.7 https://trial.medpath.com/news/stockwatch-sangamo-shares-surge-on-shorter-pathway-for-fabry-candidate 2024-10-26T18:26:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stockwatch-sangamo-shares-surge-on-shorter-pathway-for-fabry-candidate 2024-10-26T18:26:37+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-valiant-results-presented-at-kidney-week-show-pegcetacoplan-treatment-effect-in-sobi 2024-10-26T18:17:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-valiant-results-presented-at-kidney-week-show-pegcetacoplan-treatment-effect-in-sobi 2024-10-26T18:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/behind-the-ecog-acrin-e1910-trial-blinatumomab-in-b-all-targeted-oncology 2024-10-26T18:16:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/behind-the-ecog-acrin-e1910-trial-blinatumomab-in-b-all-targeted-oncology 2024-10-26T18:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-26T18:14:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pivotal-valiant-results-presented-at-kidney-week-highlight-strength-of-pegcetacoplan 2024-10-26T18:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/jennifer-lai-yee-md-phd-mph-honing-in-on-sparsentan-s-benefit-in-genetic-fsgs 2024-10-26T17:34:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jennifer-lai-yee-md-phd-mph-honing-in-on-sparsentan-s-benefit-in-genetic-fsgs 2024-10-26T17:34:29+00:00 weekly 0.7 https://trial.medpath.com/news/mhra-greenlights-donanemab-for-early-stage-alzheimer-s-disease-news-medical 2024-10-26T17:29:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mhra-greenlights-donanemab-for-early-stage-alzheimer-s-disease-news-medical 2024-10-26T17:29:07+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-program-of-vidofludimus-calcium-continues-chmp-recommends-approval-for 2024-10-26T17:16:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-program-of-vidofludimus-calcium-continues-chmp-recommends-approval-for 2024-10-26T17:16:44+00:00 weekly 0.7 https://trial.medpath.com/news/travere-therapeutics-presents-data-reinforcing-clinical-globenewswire 2024-10-26T17:02:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/travere-therapeutics-presents-data-reinforcing-clinical-globenewswire 2024-10-26T17:02:28+00:00 weekly 0.7 https://trial.medpath.com/news/fighting-triple-negative-breast-cancer-is-hard-but-not-impossible 2024-10-26T16:39:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fighting-triple-negative-breast-cancer-is-hard-but-not-impossible 2024-10-26T16:39:57+00:00 weekly 0.7 https://trial.medpath.com/news/kat-aki-tailored-ehr-alerts-fail-to-improve-aki-management-in-hospitalized-patients 2024-10-26T16:14:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kat-aki-tailored-ehr-alerts-fail-to-improve-aki-management-in-hospitalized-patients 2024-10-26T16:14:08+00:00 weekly 0.7 https://trial.medpath.com/news/ribox-therapeutics-announces-fda-clearance-for-ind-application-of-rxrg001-the-biospace 2024-10-26T15:33:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ribox-therapeutics-announces-fda-clearance-for-ind-application-of-rxrg001-the-biospace 2024-10-26T15:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/disc-medicine-presents-positive-data-from-sad-cohorts-of-a-phase-1b-trial-in-patients-with 2024-10-26T15:33:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/disc-medicine-presents-positive-data-from-sad-cohorts-of-a-phase-1b-trial-in-patients-with 2024-10-26T15:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/kind-announces-fda-granted-orphan-drug-designation-odd-for-and017-in-the-biospace 2024-10-26T15:33:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kind-announces-fda-granted-orphan-drug-designation-odd-for-and017-in-the-biospace 2024-10-26T15:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/evecxia-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-the-fda 2024-10-26T15:33:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evecxia-therapeutics-announces-successful-completion-of-pre-ind-meeting-with-the-fda 2024-10-26T15:33:37+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-provides-updates-on-multiple-kidney-programs-at-the-american-society-of-biospace 2024-10-26T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-provides-updates-on-multiple-kidney-programs-at-the-american-society-of-biospace 2024-10-26T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/precision-medicine-approach-shows-promise-for-anaplastic-thyroid-cancer-medpage-today 2024-10-26T15:32:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precision-medicine-approach-shows-promise-for-anaplastic-thyroid-cancer-medpage-today 2024-10-26T15:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/top-5-infectious-disease-news-stories-week-of-october-18-25-contagion-live 2024-10-26T15:07:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-5-infectious-disease-news-stories-week-of-october-18-25-contagion-live 2024-10-26T15:07:45+00:00 weekly 0.7 https://trial.medpath.com/news/driving-pressure-during-general-anesthesia-for-minimally-invasive-abdominal-surgery-generator 2024-10-26T14:36:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/driving-pressure-during-general-anesthesia-for-minimally-invasive-abdominal-surgery-generator 2024-10-26T14:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-immunotherapy-options-based-on-mutations-for-nsclc-cancer-network 2024-10-26T14:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluating-immunotherapy-options-based-on-mutations-for-nsclc-cancer-network 2024-10-26T14:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/day-2-recap-fall-clinical-2024-dermatology-times 2024-10-26T14:07:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/day-2-recap-fall-clinical-2024-dermatology-times 2024-10-26T14:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/upadacitinib-shows-long-term-benefits-in-teens-with-atopic-dermatitis-medpage-today 2024-10-26T13:50:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upadacitinib-shows-long-term-benefits-in-teens-with-atopic-dermatitis-medpage-today 2024-10-26T13:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-shows-promise-reduces-uacr-in-nondiabetic-kidney-disease-hcplive 2024-10-26T13:22:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-shows-promise-reduces-uacr-in-nondiabetic-kidney-disease-hcplive 2024-10-26T13:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/stx-478-may-improve-therapeutic-index-vs-other-pi3k-inhibitors-in-cancer 2024-10-26T13:11:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stx-478-may-improve-therapeutic-index-vs-other-pi3k-inhibitors-in-cancer 2024-10-26T13:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/go-fgfr-tyra-s-urothelial-data-upbeat-stock-down-bioworld 2024-10-26T13:10:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/go-fgfr-tyra-s-urothelial-data-upbeat-stock-down-bioworld 2024-10-26T13:10:12+00:00 weekly 0.7 https://trial.medpath.com/news/september-conferences-deliver-wave-of-positive-clinical-updates-bioworld 2024-10-26T13:10:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-conferences-deliver-wave-of-positive-clinical-updates-bioworld 2024-10-26T13:10:10+00:00 weekly 0.7 https://trial.medpath.com/news/available-therapeutics-and-upcoming-advancements-in-atopic-dermatitis-and-prurigo-nodularis 2024-10-26T13:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/available-therapeutics-and-upcoming-advancements-in-atopic-dermatitis-and-prurigo-nodularis 2024-10-26T13:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/new-phase-3b-findings-suggest-lebrikizumab-improved-skin-itch-for-atopic-dermatitis 2024-10-26T12:48:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-phase-3b-findings-suggest-lebrikizumab-improved-skin-itch-for-atopic-dermatitis 2024-10-26T12:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/empagliflozin-benefits-on-kidney-disease-progression-death-continue-for-1-year-post 2024-10-26T12:37:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/empagliflozin-benefits-on-kidney-disease-progression-death-continue-for-1-year-post 2024-10-26T12:37:18+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-to-present-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-26T12:30:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-to-present-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-26T12:30:53+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacist-prescribed-birth-control-emerges-as-key-solution-to-address-u-s-maternal-health-deserts 2024-10-26T12:25:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacist-prescribed-birth-control-emerges-as-key-solution-to-address-u-s-maternal-health-deserts 2024-10-26T12:25:42+00:00 weekly 0.7 https://trial.medpath.com/news/will-herrington-mbbs-md-ma-empagliflozin-follow-up-data-informs-clinical-care-for-ckd 2024-10-26T12:05:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/will-herrington-mbbs-md-ma-empagliflozin-follow-up-data-informs-clinical-care-for-ckd 2024-10-26T12:05:59+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-october-21-october-25 2024-10-26T11:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-happened-in-optometry-this-week-october-21-october-25 2024-10-26T11:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/and017-receives-fda-orphan-drug-designation-for-sickle-cell-disease-hcplive 2024-10-26T11:30:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/and017-receives-fda-orphan-drug-designation-for-sickle-cell-disease-hcplive 2024-10-26T11:30:37+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-us-fda-approval-for-affera-mapping-and-ablation-system-with-sphere-9-catheter 2024-10-26T11:30:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-receives-us-fda-approval-for-affera-mapping-and-ablation-system-with-sphere-9-catheter 2024-10-26T11:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/pioneering-trial-to-test-multiple-new-treatments-for-glioblastoma-news-medical 2024-10-26T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pioneering-trial-to-test-multiple-new-treatments-for-glioblastoma-news-medical 2024-10-26T11:27:01+00:00 weekly 0.7 https://trial.medpath.com/news/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-1 2024-10-26T10:13:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-impact-clinical-trials-generate-promising-results-for-improving-kidney-health-part-1 2024-10-26T10:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-rhhby-earnings-drug-pipeline-regulatory-news 2024-10-26T09:53:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-roundup-rhhby-earnings-drug-pipeline-regulatory-news 2024-10-26T09:53:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-new-drug-application-for-pixclara-for-glioma-imaging-cure-today 2024-10-26T09:06:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-new-drug-application-for-pixclara-for-glioma-imaging-cure-today 2024-10-26T09:06:38+00:00 weekly 0.7 https://trial.medpath.com/news/community-pharmacies-urged-to-adopt-clinical-program-mindset-for-service-expansion 2024-10-26T08:58:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/community-pharmacies-urged-to-adopt-clinical-program-mindset-for-service-expansion 2024-10-26T08:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/leveraging-ai-to-optimize-precision-immunotherapy-at-vanderbilt 2024-10-26T08:16:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leveraging-ai-to-optimize-precision-immunotherapy-at-vanderbilt 2024-10-26T08:16:03+00:00 weekly 0.7 https://trial.medpath.com/news/the-wee1-inhibitor-apr-1051-shows-early-safety-and-tolerability-in-advanced-mutated 2024-10-26T08:06:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-wee1-inhibitor-apr-1051-shows-early-safety-and-tolerability-in-advanced-mutated 2024-10-26T08:06:49+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-stock-hits-52-week-low-at-181-25-amid-market-challenges-investing-com 2024-10-26T08:04:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-stock-hits-52-week-low-at-181-25-amid-market-challenges-investing-com 2024-10-26T08:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/2024-2025-respiratory-vaccine-guidelines-key-updates-for-covid-19-flu-rsv-and-pneumococcal-vaccines 2024-10-26T08:00:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/2024-2025-respiratory-vaccine-guidelines-key-updates-for-covid-19-flu-rsv-and-pneumococcal-vaccines 2024-10-26T08:00:23+00:00 weekly 0.7 https://trial.medpath.com/news/swedish-studies-show-rising-cancer-rates-during-pregnancy-but-favorable-outcomes-for-breast-cancer-patients 2024-10-26T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/swedish-studies-show-rising-cancer-rates-during-pregnancy-but-favorable-outcomes-for-breast-cancer-patients 2024-10-26T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/epinephrine-film-offers-oral-allergy-relief-in-few-minutes-study-allergic-living 2024-10-26T07:25:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epinephrine-film-offers-oral-allergy-relief-in-few-minutes-study-allergic-living 2024-10-26T07:25:34+00:00 weekly 0.7 https://trial.medpath.com/news/immunitybio-soars-56-in-a-day-is-this-cancer-breakthrough-the-next-30-stock 2024-10-26T07:12:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunitybio-soars-56-in-a-day-is-this-cancer-breakthrough-the-next-30-stock 2024-10-26T07:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-mdl-101-for-congenital-muscular-dystrophy-type-1a 2024-10-26T07:10:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-mdl-101-for-congenital-muscular-dystrophy-type-1a 2024-10-26T07:10:37+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-october-25-2024 2024-10-26T07:07:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-october-25-2024 2024-10-26T07:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-gedeon-richter-ink-deal-to-develop-novel-targets-for-neuropsychiatric-conditions 2024-10-26T06:36:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-gedeon-richter-ink-deal-to-develop-novel-targets-for-neuropsychiatric-conditions 2024-10-26T06:36:51+00:00 weekly 0.7 https://trial.medpath.com/news/zaltenibart-receives-fda-rare-pediatric-disease-designation-for-c3-glomerulopathy 2024-10-26T06:26:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/zaltenibart-receives-fda-rare-pediatric-disease-designation-for-c3-glomerulopathy 2024-10-26T06:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/recent-fda-guidance-signals-future-growth-for-decentralized-clinical-trials-jd-supra 2024-10-26T06:19:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-fda-guidance-signals-future-growth-for-decentralized-clinical-trials-jd-supra 2024-10-26T06:19:22+00:00 weekly 0.7 https://trial.medpath.com/news/liquid-biopsy-imaging-may-show-benefit-in-li-fraumeni-syndrome-screening 2024-10-26T06:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liquid-biopsy-imaging-may-show-benefit-in-li-fraumeni-syndrome-screening 2024-10-26T06:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/ribociclib-recognized-by-nccn-clinical-practice-guidelines-as-category-1-pharmacy-times 2024-10-26T06:07:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ribociclib-recognized-by-nccn-clinical-practice-guidelines-as-category-1-pharmacy-times 2024-10-26T06:07:28+00:00 weekly 0.7 https://trial.medpath.com/news/trial-highlights-potential-next-gen-biologic-for-lung-cancer 2024-10-26T05:26:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-highlights-potential-next-gen-biologic-for-lung-cancer 2024-10-26T05:26:44+00:00 weekly 0.7 https://trial.medpath.com/news/semaglutide-may-reduce-alzheimer-s-risk-in-diabetics-news-medical 2024-10-26T05:11:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/semaglutide-may-reduce-alzheimer-s-risk-in-diabetics-news-medical 2024-10-26T05:11:01+00:00 weekly 0.7 https://trial.medpath.com/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high-statistical-significance-in-positive-phase-2-study-in-chronic-inducible-urticaria 2024-10-26T05:10:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celldex-announces-barzolvolimab-met-all-primary-and-secondary-endpoints-with-high-statistical-significance-in-positive-phase-2-study-in-chronic-inducible-urticaria 2024-10-26T05:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-group-expands-psilocybin-clinical-trials-tipranks-com 2024-10-26T04:16:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-group-expands-psilocybin-clinical-trials-tipranks-com 2024-10-26T04:16:19+00:00 weekly 0.7 https://trial.medpath.com/news/leo-s-adbry-demonstrates-long-term-efficacy-in-atopic-dermatitis 2024-10-26T04:14:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leo-s-adbry-demonstrates-long-term-efficacy-in-atopic-dermatitis 2024-10-26T04:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/dll3-targeted-adc-produces-responses-in-previously-treated-es-sclc 2024-10-26T04:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dll3-targeted-adc-produces-responses-in-previously-treated-es-sclc 2024-10-26T04:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-shows-curcuma-based-nutritional-supplements-may-be-associated-with-the 2024-10-26T04:06:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-shows-curcuma-based-nutritional-supplements-may-be-associated-with-the 2024-10-26T04:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-oral-antibiotic-orlynvah-for-uutis-investing-com-nigeria 2024-10-26T04:03:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-oral-antibiotic-orlynvah-for-uutis-investing-com-nigeria 2024-10-26T04:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-announces-submission-of-the-tnx-102-sl-new-drug-application 2024-10-26T03:53:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tonix-pharmaceuticals-announces-submission-of-the-tnx-102-sl-new-drug-application 2024-10-26T03:53:22+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified 2024-10-26T03:43:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified 2024-10-26T03:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/blockbuster-obesity-drugs-also-may-slow-kidney-disease-vumc-news 2024-10-26T03:10:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blockbuster-obesity-drugs-also-may-slow-kidney-disease-vumc-news 2024-10-26T03:10:48+00:00 weekly 0.7 https://trial.medpath.com/news/tms-for-the-treatment-of-ocd-psychiatric-times 2024-10-26T03:01:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tms-for-the-treatment-of-ocd-psychiatric-times 2024-10-26T03:01:24+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-backed-agomab-raises-89m-to-advance-fibrotic-disease-treatments 2024-10-26T02:59:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-backed-agomab-raises-89m-to-advance-fibrotic-disease-treatments 2024-10-26T02:59:23+00:00 weekly 0.7 https://trial.medpath.com/news/nab-sirolimus-and-its-role-in-pecoma-treatment-targeted-oncology 2024-10-26T02:01:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nab-sirolimus-and-its-role-in-pecoma-treatment-targeted-oncology 2024-10-26T02:01:45+00:00 weekly 0.7 https://trial.medpath.com/news/pancreatic-cancer-market-to-hit-us-11-5-billion-by-2033 2024-10-26T02:00:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pancreatic-cancer-market-to-hit-us-11-5-billion-by-2033 2024-10-26T02:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/asthma-drug-does-not-speed-covid-19-recovery-study-vumc-news 2024-10-26T01:25:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asthma-drug-does-not-speed-covid-19-recovery-study-vumc-news 2024-10-26T01:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/nurse-led-discussion-on-diet-during-radiation-may-boost-quality-of-life-oncology-nursing-news 2024-10-26T01:06:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurse-led-discussion-on-diet-during-radiation-may-boost-quality-of-life-oncology-nursing-news 2024-10-26T01:06:42+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-operator-zai-lab-surges-to-16-month-high-on-lung-cancer-drug-trial-results 2024-10-26T00:47:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-operator-zai-lab-surges-to-16-month-high-on-lung-cancer-drug-trial-results 2024-10-26T00:47:05+00:00 weekly 0.7 https://trial.medpath.com/news/new-phase-3-data-shows-high-rate-of-atopic-dermatitis-clearance-using-tapinarof-cream-1 2024-10-26T00:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-phase-3-data-shows-high-rate-of-atopic-dermatitis-clearance-using-tapinarof-cream-1 2024-10-26T00:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/optimistic-buy-rating-for-ideaya-biosciences-driven-by-promising-ide397-data-and-strong 2024-10-26T00:13:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimistic-buy-rating-for-ideaya-biosciences-driven-by-promising-ide397-data-and-strong 2024-10-26T00:13:20+00:00 weekly 0.7 https://trial.medpath.com/news/micurx-announces-the-successful-completion-of-phase-1-clinical-trial-of-mrx-5-in-australia 2024-10-25T23:30:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/micurx-announces-the-successful-completion-of-phase-1-clinical-trial-of-mrx-5-in-australia 2024-10-25T23:30:17+00:00 weekly 0.7 https://trial.medpath.com/news/fabry-disease-gene-therapy-study-data-enough-for-fda-submission 2024-10-25T23:08:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fabry-disease-gene-therapy-study-data-enough-for-fda-submission 2024-10-25T23:08:54+00:00 weekly 0.7 https://trial.medpath.com/news/genedx-reveals-new-findings-from-newborn-genetic-screening-study-clinical-trials-arena 2024-10-25T22:49:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genedx-reveals-new-findings-from-newborn-genetic-screening-study-clinical-trials-arena 2024-10-25T22:49:33+00:00 weekly 0.7 https://trial.medpath.com/news/immunitybio-commences-cd19-t-hank-cell-therapy-trial-for-nhl 2024-10-25T22:49:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunitybio-commences-cd19-t-hank-cell-therapy-trial-for-nhl 2024-10-25T22:49:32+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv-biospace 2024-10-25T22:46:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv-biospace 2024-10-25T22:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T22:35:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T22:35:52+00:00 weekly 0.7 https://trial.medpath.com/news/the-potential-of-device-assisted-therapies-in-pd-insights-from-the-phase-1-2-dive-i-trial 2024-10-25T22:06:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-potential-of-device-assisted-therapies-in-pd-insights-from-the-phase-1-2-dive-i-trial 2024-10-25T22:06:21+00:00 weekly 0.7 https://trial.medpath.com/news/accord-biopharma-announces-fda-approval-of-imuldosa-ustekinumab-srlf-jd-supra 2024-10-25T22:03:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accord-biopharma-announces-fda-approval-of-imuldosa-ustekinumab-srlf-jd-supra 2024-10-25T22:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-s-innovative-affera-system-gains-fda-approval-boosting-ep-market-prospects 2024-10-25T21:57:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-s-innovative-affera-system-gains-fda-approval-boosting-ep-market-prospects 2024-10-25T21:57:51+00:00 weekly 0.7 https://trial.medpath.com/news/radicava-ors-slows-als-disease-progression-improves-survival-als-news-today 2024-10-25T21:33:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radicava-ors-slows-als-disease-progression-improves-survival-als-news-today 2024-10-25T21:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/hemophilia-a-b-prophylaxis-therapy-hympavzi-may-soon-be-available-in-us 2024-10-25T21:26:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hemophilia-a-b-prophylaxis-therapy-hympavzi-may-soon-be-available-in-us 2024-10-25T21:26:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-estradiol-gel-0-06-for-women-post-menopause-pharmacy-times 2024-10-25T21:22:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-estradiol-gel-0-06-for-women-post-menopause-pharmacy-times 2024-10-25T21:22:08+00:00 weekly 0.7 https://trial.medpath.com/news/orexo-initiates-new-study-of-ox640-in-participants-with-allergic-rhiniti 2024-10-25T21:10:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orexo-initiates-new-study-of-ox640-in-participants-with-allergic-rhiniti 2024-10-25T21:10:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-orlynvah-sulopenem-etzadroxil-and-probenecid-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-10-25T21:10:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-orlynvah-sulopenem-etzadroxil-and-probenecid-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-10-25T21:10:46+00:00 weekly 0.7 https://trial.medpath.com/news/ani-pharmaceuticals-announces-fda-approval-of-estradiol-gel-0-06-markets-insider 2024-10-25T20:50:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ani-pharmaceuticals-announces-fda-approval-of-estradiol-gel-0-06-markets-insider 2024-10-25T20:50:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novel-treatment-for-utis-medpage-today 2024-10-25T20:48:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novel-treatment-for-utis-medpage-today 2024-10-25T20:48:22+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-announces-fda-approval-of-orlynvah-markets-insider 2024-10-25T20:46:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-announces-fda-approval-of-orlynvah-markets-insider 2024-10-25T20:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T20:46:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T20:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/with-fda-approval-iterum-s-patience-pays-off-bioworld 2024-10-25T20:44:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/with-fda-approval-iterum-s-patience-pays-off-bioworld 2024-10-25T20:44:08+00:00 weekly 0.7 https://trial.medpath.com/news/photonpharma-installs-new-ceo-as-ovarian-cancer-drug-trial-launches-bizwest 2024-10-25T20:39:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/photonpharma-installs-new-ceo-as-ovarian-cancer-drug-trial-launches-bizwest 2024-10-25T20:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/vantis-vascular-receives-fda-clearance-for-its-crossfasttm-guide 2024-10-25T20:17:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vantis-vascular-receives-fda-clearance-for-its-crossfasttm-guide 2024-10-25T20:17:15+00:00 weekly 0.7 https://trial.medpath.com/news/regulatory-collaboration-on-mpox-treatments-summarized-in-report 2024-10-25T20:12:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regulatory-collaboration-on-mpox-treatments-summarized-in-report 2024-10-25T20:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-10-25T19:45:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-oral-sulopenem-for-the-treatment-of-uncomplicated-urinary-tract-infections 2024-10-25T19:45:07+00:00 weekly 0.7 https://trial.medpath.com/news/immunitybio-soars-56-in-a-day-is-this-cancer-breakthrough-the-next-30-stock 2024-10-25T19:23:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunitybio-soars-56-in-a-day-is-this-cancer-breakthrough-the-next-30-stock 2024-10-25T19:23:15+00:00 weekly 0.7 https://trial.medpath.com/news/qurient-launches-clinical-trial-for-acute-myeloid-leukemia-treatment-with-adrixetinib-q702 2024-10-25T19:20:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qurient-launches-clinical-trial-for-acute-myeloid-leukemia-treatment-with-adrixetinib-q702 2024-10-25T19:20:30+00:00 weekly 0.7 https://trial.medpath.com/news/single-treatment-with-crispr-gene-editing-therapy-offers-hope-for-hereditary-angioedema-patients 2024-10-25T18:51:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/single-treatment-with-crispr-gene-editing-therapy-offers-hope-for-hereditary-angioedema-patients 2024-10-25T18:51:26+00:00 weekly 0.7 https://trial.medpath.com/news/a-promising-candidate-for-friedreich-s-ataxia-managed-healthcare-executive 2024-10-25T18:43:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-promising-candidate-for-friedreich-s-ataxia-managed-healthcare-executive 2024-10-25T18:43:54+00:00 weekly 0.7 https://trial.medpath.com/news/caris-life-sciences-ecog-acrin-partner-to-interrogate-landmark-tailorx-breast-cancer-trial 2024-10-25T18:29:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caris-life-sciences-ecog-acrin-partner-to-interrogate-landmark-tailorx-breast-cancer-trial 2024-10-25T18:29:51+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-combinations-dominate-frontline-discussions-in-advanced-rcc-onclive 2024-10-25T18:26:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-combinations-dominate-frontline-discussions-in-advanced-rcc-onclive 2024-10-25T18:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-oral-sulopenem-orlynvah-for-uncomplicated-urinary-tract-infections 2024-10-25T18:22:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-oral-sulopenem-orlynvah-for-uncomplicated-urinary-tract-infections 2024-10-25T18:22:13+00:00 weekly 0.7 https://trial.medpath.com/news/pipettes-take-small-molecule-inhibitors-from-discovery-to-clinical-trials-selectscience 2024-10-25T18:09:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipettes-take-small-molecule-inhibitors-from-discovery-to-clinical-trials-selectscience 2024-10-25T18:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-newly-fda-approved-eczema-drug-improves-skin-and-itch-in-patients-previously 2024-10-25T18:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-newly-fda-approved-eczema-drug-improves-skin-and-itch-in-patients-previously 2024-10-25T18:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-avd-prolongs-pfs-vs-brentuximab-vedotin-plus-avd-in-advanced-stage 2024-10-25T18:07:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-avd-prolongs-pfs-vs-brentuximab-vedotin-plus-avd-in-advanced-stage 2024-10-25T18:07:29+00:00 weekly 0.7 https://trial.medpath.com/news/can-a-kidney-action-team-improve-patient-outcomes-yale-school-of-medicine 2024-10-25T18:07:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/can-a-kidney-action-team-improve-patient-outcomes-yale-school-of-medicine 2024-10-25T18:07:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-3-lugano-trial-of-duravyu-for-wet-amd-healio 2024-10-25T18:00:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-phase-3-lugano-trial-of-duravyu-for-wet-amd-healio 2024-10-25T18:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-asa-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv 2024-10-25T17:53:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-asa-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv 2024-10-25T17:53:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-sulopenem-etzadroxil-and-probenecid-for-uncomplicated-urinary-tract-infections 2024-10-25T17:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-sulopenem-etzadroxil-and-probenecid-for-uncomplicated-urinary-tract-infections 2024-10-25T17:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-oral-sulopenem-etzadroxil-and-probenecid-for-uncomplicated-urinary-tract-infections 2024-10-25T17:37:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-oral-sulopenem-etzadroxil-and-probenecid-for-uncomplicated-urinary-tract-infections 2024-10-25T17:37:19+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-medtronic-s-new-all-in-one-mapping-and-ablation-system-for-afib 2024-10-25T17:32:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-new-all-in-one-mapping-and-ablation-system-for-afib 2024-10-25T17:32:44+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-mapping-dual-energy-catheter-ablation-system-for-persistent-af-healio 2024-10-25T17:25:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-mapping-dual-energy-catheter-ablation-system-for-persistent-af-healio 2024-10-25T17:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/could-ozempic-lower-the-risk-of-alzheimer-s-newsnation 2024-10-25T17:24:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/could-ozempic-lower-the-risk-of-alzheimer-s-newsnation 2024-10-25T17:24:23+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-receives-us-fda-approval-of-affera-mapping-and-ablation-system-and-sphere-9-catheter 2024-10-25T17:23:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-receives-us-fda-approval-of-affera-mapping-and-ablation-system-and-sphere-9-catheter 2024-10-25T17:23:39+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-gets-fda-approval-of-orlynvah-for-treatment-of-urinary-tract-infections 2024-10-25T17:19:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-gets-fda-approval-of-orlynvah-for-treatment-of-urinary-tract-infections 2024-10-25T17:19:38+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-wins-fda-approval-for-affera-mapping-and-ablation-system-yahoo-finance 2024-10-25T17:10:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-wins-fda-approval-for-affera-mapping-and-ablation-system-yahoo-finance 2024-10-25T17:10:03+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-starts-new-trial-to-assess-early-use-benefit-of-heartmate-3 2024-10-25T16:49:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-starts-new-trial-to-assess-early-use-benefit-of-heartmate-3 2024-10-25T16:49:35+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-gets-fda-approval-of-orlynvah-for-treatment-of-urinary-tract-infections 2024-10-25T16:43:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-gets-fda-approval-of-orlynvah-for-treatment-of-urinary-tract-infections 2024-10-25T16:43:23+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-never-told-patients-in-leqembi-clinical-trials-they-faced-higher-risk-of-brain-bleeds 2024-10-25T16:41:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eisai-never-told-patients-in-leqembi-clinical-trials-they-faced-higher-risk-of-brain-bleeds 2024-10-25T16:41:52+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-oral-sulopenem-for-uncomplicated-urinary-tract-infection-urology-times 2024-10-25T16:41:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-oral-sulopenem-for-uncomplicated-urinary-tract-infection-urology-times 2024-10-25T16:41:31+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-shares-soar-on-fda-s-orlynvah-approval-morningstar 2024-10-25T16:37:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-shares-soar-on-fda-s-orlynvah-approval-morningstar 2024-10-25T16:37:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-oral-sulopenem-for-treatment-of-uncomplicated-utis-contemporary-ob-gyn 2024-10-25T16:36:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-oral-sulopenem-for-treatment-of-uncomplicated-utis-contemporary-ob-gyn 2024-10-25T16:36:38+00:00 weekly 0.7 https://trial.medpath.com/news/jubilant-therapeutics-announces-first-patient-dosing-in-global-clinical-trials-for-jbi-802-and-jbi-778 2024-10-25T16:27:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jubilant-therapeutics-announces-first-patient-dosing-in-global-clinical-trials-for-jbi-802-and-jbi-778 2024-10-25T16:27:39+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-wins-fda-approval-for-affera-mapping-and-ablation-system-medtech-dive 2024-10-25T16:25:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-wins-fda-approval-for-affera-mapping-and-ablation-system-medtech-dive 2024-10-25T16:25:53+00:00 weekly 0.7 https://trial.medpath.com/news/criteriamapper-establishing-the-automatic-identification-of-clinical-trial-cohorts-from-nature 2024-10-25T16:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/criteriamapper-establishing-the-automatic-identification-of-clinical-trial-cohorts-from-nature 2024-10-25T16:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/mdma-therapy-for-mental-health-conditions-do-the-benefits-outweigh-the-risks 2024-10-25T16:02:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mdma-therapy-for-mental-health-conditions-do-the-benefits-outweigh-the-risks 2024-10-25T16:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/a-potential-first-in-class-selective-ck1a-molecular-glue-degrader 2024-10-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-potential-first-in-class-selective-ck1a-molecular-glue-degrader 2024-10-25T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-announces-recruitment 2024-10-25T15:56:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-group-s-nasdaq-listed-associate-psyence-biomedical-announces-recruitment 2024-10-25T15:56:17+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-presents-final-results-of-ecztend-long-term-adbry-r-trial-tralokinumab 2024-10-25T15:56:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leo-pharma-presents-final-results-of-ecztend-long-term-adbry-r-trial-tralokinumab 2024-10-25T15:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/maze-therapeutics-reports-positive-first-in-human-data-from-phase-1-healthy-volunteer 2024-10-25T15:56:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maze-therapeutics-reports-positive-first-in-human-data-from-phase-1-healthy-volunteer 2024-10-25T15:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/genomics-series-navigating-regulatory-challenges-in-the-era-of-cell-and-gene-therapies 2024-10-25T15:31:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genomics-series-navigating-regulatory-challenges-in-the-era-of-cell-and-gene-therapies 2024-10-25T15:31:10+00:00 weekly 0.7 https://trial.medpath.com/news/vantis-vascular-receives-fda-clearance-for-its-crossfasttm-guide 2024-10-25T15:30:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vantis-vascular-receives-fda-clearance-for-its-crossfasttm-guide 2024-10-25T15:30:33+00:00 weekly 0.7 https://trial.medpath.com/news/fostering-regulatory-collaboration-to-improve-access-to-mpox-medicines 2024-10-25T15:29:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fostering-regulatory-collaboration-to-improve-access-to-mpox-medicines 2024-10-25T15:29:37+00:00 weekly 0.7 https://trial.medpath.com/news/second-alzheimer-s-drug-rejected-by-nice-on-the-same-day-it-is-approved-in-the-uk 2024-10-25T15:24:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/second-alzheimer-s-drug-rejected-by-nice-on-the-same-day-it-is-approved-in-the-uk 2024-10-25T15:24:20+00:00 weekly 0.7 https://trial.medpath.com/news/teva-mabxience-expand-partnership-for-additional-oncology-biosimilar-candidate 2024-10-25T15:21:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/teva-mabxience-expand-partnership-for-additional-oncology-biosimilar-candidate 2024-10-25T15:21:39+00:00 weekly 0.7 https://trial.medpath.com/news/eligible-infants-included-in-neonatal-clinical-trials-and-reasons-for-noninclusion 2024-10-25T15:16:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eligible-infants-included-in-neonatal-clinical-trials-and-reasons-for-noninclusion 2024-10-25T15:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/cadonilimab-is-effective-and-safe-in-recurrent-cervical-cancer-nature-reviews-clinical-oncology 2024-10-25T15:15:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cadonilimab-is-effective-and-safe-in-recurrent-cervical-cancer-nature-reviews-clinical-oncology 2024-10-25T15:15:31+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-globenewswire 2024-10-25T15:14:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-globenewswire 2024-10-25T15:14:07+00:00 weekly 0.7 https://trial.medpath.com/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T15:11:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iterum-therapeutics-receives-u-s-fda-approval-of-orlynvahtm-oral-sulopenem-for-the 2024-10-25T15:11:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-novel-schizophrenia-drug-psychiatry-and-behavioral-health-jama-network 2024-10-25T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-novel-schizophrenia-drug-psychiatry-and-behavioral-health-jama-network 2024-10-25T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-reports-positive-data-from-phase-ii-study-of-ntla-2002-for-hae-yahoo-finance 2024-10-25T15:04:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-reports-positive-data-from-phase-ii-study-of-ntla-2002-for-hae-yahoo-finance 2024-10-25T15:04:27+00:00 weekly 0.7 https://trial.medpath.com/news/ultimovacs-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv 2024-10-25T15:02:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ultimovacs-announces-publication-of-phase-ii-focus-trial-results-on-medrxiv 2024-10-25T15:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-reports-positive-data-from-phase-ii-study-of-ntla-2002-for-hae 2024-10-25T14:49:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-reports-positive-data-from-phase-ii-study-of-ntla-2002-for-hae 2024-10-25T14:49:23+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-invests-800m-in-manufacturing-amgen-sets-small-discount-for-eylea-biosimilar 2024-10-25T14:40:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-invests-800m-in-manufacturing-amgen-sets-small-discount-for-eylea-biosimilar 2024-10-25T14:40:20+00:00 weekly 0.7 https://trial.medpath.com/news/young-adult-breast-cancer-survivor-why-i-joined-a-clinical-trial-at-md-anderson 2024-10-25T14:33:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/young-adult-breast-cancer-survivor-why-i-joined-a-clinical-trial-at-md-anderson 2024-10-25T14:33:58+00:00 weekly 0.7 https://trial.medpath.com/news/weight-management-market-continues-to-grow-benefits-and-pensions-monitor 2024-10-25T14:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weight-management-market-continues-to-grow-benefits-and-pensions-monitor 2024-10-25T14:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-25T14:03:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-late-breaking-positive-phase-3-data-in-chronic-spontaneous 2024-10-25T14:03:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pfizer-s-rsv-vax-abrysvo-in-adults-at-increased-risk-contract-pharma 2024-10-25T14:03:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pfizer-s-rsv-vax-abrysvo-in-adults-at-increased-risk-contract-pharma 2024-10-25T14:03:15+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-r-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous-biospace 2024-10-25T14:03:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-r-dupilumab-late-breaking-positive-phase-3-data-in-chronic-spontaneous-biospace 2024-10-25T14:03:12+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-group-s-nasdaq-listed-associate-psyence-globenewswire 2024-10-25T13:56:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psyence-group-s-nasdaq-listed-associate-psyence-globenewswire 2024-10-25T13:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-biopharma-s-ysja-rabies-vaccine-heads-to-phase-iii-trial-contract-pharma 2024-10-25T13:44:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lakeshore-biopharma-s-ysja-rabies-vaccine-heads-to-phase-iii-trial-contract-pharma 2024-10-25T13:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/farrsight-twin-technology-transforms-cancer-treatment-research-news-medical 2024-10-25T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/farrsight-twin-technology-transforms-cancer-treatment-research-news-medical 2024-10-25T13:14:46+00:00 weekly 0.7 https://trial.medpath.com/news/pa-psychedelic-bulletin-178-va-funding-of-lykos-phase-3-definitely-a-possibility 2024-10-25T13:14:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pa-psychedelic-bulletin-178-va-funding-of-lykos-phase-3-definitely-a-possibility 2024-10-25T13:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/a-potential-first-in-class-ent1-inhibitor-for-immuno-oncology-indications-derived-from-dilazep 2024-10-25T13:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-potential-first-in-class-ent1-inhibitor-for-immuno-oncology-indications-derived-from-dilazep 2024-10-25T13:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/jubilant-therapeutics-inc-announces-first-patient-dosing-in-global-clinical-trials 2024-10-25T13:04:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jubilant-therapeutics-inc-announces-first-patient-dosing-in-global-clinical-trials 2024-10-25T13:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified 2024-10-25T13:04:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified 2024-10-25T13:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/polestar-results-show-pfs-benefit-of-aumolertinib-in-nsclc-targeted-oncology 2024-10-25T13:01:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/polestar-results-show-pfs-benefit-of-aumolertinib-in-nsclc-targeted-oncology 2024-10-25T13:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/intellia-s-crispr-gene-editor-cuts-hereditary-angioedema-attacks-by-81-in-phase-ii-study 2024-10-25T12:59:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intellia-s-crispr-gene-editor-cuts-hereditary-angioedema-attacks-by-81-in-phase-ii-study 2024-10-25T12:59:48+00:00 weekly 0.7 https://trial.medpath.com/news/bioduro-sundia-expands-shanghai-operations-with-new-kilogram-laboratory-and-compound-management-center 2024-10-25T12:50:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bioduro-sundia-expands-shanghai-operations-with-new-kilogram-laboratory-and-compound-management-center 2024-10-25T12:50:15+00:00 weekly 0.7 https://trial.medpath.com/news/cannabis-medicine-trials-for-refractory-epilepsy-to-start-in-2025 2024-10-25T12:47:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cannabis-medicine-trials-for-refractory-epilepsy-to-start-in-2025 2024-10-25T12:47:49+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified-stock-titan 2024-10-25T12:47:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified-stock-titan 2024-10-25T12:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified-quantisnow 2024-10-25T12:41:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lakeshore-biopharma-granted-phase-iii-clinical-trial-approval-to-explore-simplified-quantisnow 2024-10-25T12:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/mindmed-to-lead-first-lsd-phase-3-trials-for-anxiety-drug-discovery-and-development 2024-10-25T12:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindmed-to-lead-first-lsd-phase-3-trials-for-anxiety-drug-discovery-and-development 2024-10-25T12:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/lakeshore-s-ysja-rabies-vaccine-receives-approval-for-phase-iii-trial-in-china-tipranks 2024-10-25T12:37:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lakeshore-s-ysja-rabies-vaccine-receives-approval-for-phase-iii-trial-in-china-tipranks 2024-10-25T12:37:53+00:00 weekly 0.7 https://trial.medpath.com/news/liquid-biopsy-advances-transform-mrd-detection-in-high-risk-breast-cancer-management 2024-10-25T12:11:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/liquid-biopsy-advances-transform-mrd-detection-in-high-risk-breast-cancer-management 2024-10-25T12:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/mapping-drug-resistance-variants-in-cancer-one-base-at-a-time-nature-genetics 2024-10-25T12:10:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mapping-drug-resistance-variants-in-cancer-one-base-at-a-time-nature-genetics 2024-10-25T12:10:49+00:00 weekly 0.7 https://trial.medpath.com/news/admare-bionnovations-cancer-research-uk-and-kisoji-biotechnology-collaborate-to 2024-10-25T12:09:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/admare-bionnovations-cancer-research-uk-and-kisoji-biotechnology-collaborate-to 2024-10-25T12:09:13+00:00 weekly 0.7 https://trial.medpath.com/news/post-hoc-analysis-of-essence-1-trial-highlights-efficacy-of-0-1-cyclosporine-solution-for 2024-10-25T12:06:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/post-hoc-analysis-of-essence-1-trial-highlights-efficacy-of-0-1-cyclosporine-solution-for 2024-10-25T12:06:56+00:00 weekly 0.7 https://trial.medpath.com/news/pet-imaging-agent-earns-fda-priority-review-in-recurrent-glioma-cancer-network 2024-10-25T12:05:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pet-imaging-agent-earns-fda-priority-review-in-recurrent-glioma-cancer-network 2024-10-25T12:05:13+00:00 weekly 0.7 https://trial.medpath.com/news/future-clinical-trials-sequencing-decisions-for-bispecifics-and-car-t-cell-therapy 2024-10-25T12:05:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/future-clinical-trials-sequencing-decisions-for-bispecifics-and-car-t-cell-therapy 2024-10-25T12:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T11:59:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T11:59:45+00:00 weekly 0.7 https://trial.medpath.com/news/alkeus-pharmaceuticals-announces-topline-results-from-saga-trial-on-ga-treatment 2024-10-25T11:39:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-announces-topline-results-from-saga-trial-on-ga-treatment 2024-10-25T11:39:19+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-starts-new-trial-to-assess-early-use-benefit-of-heartmate-3-medical-device-network 2024-10-25T11:38:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-starts-new-trial-to-assess-early-use-benefit-of-heartmate-3-medical-device-network 2024-10-25T11:38:46+00:00 weekly 0.7 https://trial.medpath.com/news/protalix-biotherapeutics-to-present-phase-i-prx-115-data-in-late-breaking-poster-at-acr 2024-10-25T11:35:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/protalix-biotherapeutics-to-present-phase-i-prx-115-data-in-late-breaking-poster-at-acr 2024-10-25T11:35:49+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-clinical-trial-of-ganaxolone-fails-to-meet-primary-endpoint-yahoo-finance 2024-10-25T11:34:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marinus-clinical-trial-of-ganaxolone-fails-to-meet-primary-endpoint-yahoo-finance 2024-10-25T11:34:09+00:00 weekly 0.7 https://trial.medpath.com/news/invitation-sobi-s-aspaveli-r-and-the-phase-3-valiant-data-in-nephrology-call 2024-10-25T11:33:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invitation-sobi-s-aspaveli-r-and-the-phase-3-valiant-data-in-nephrology-call 2024-10-25T11:33:53+00:00 weekly 0.7 https://trial.medpath.com/news/a-first-in-class-targeted-therapy-for-some-gastrointestinal-cancers 2024-10-25T11:31:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-first-in-class-targeted-therapy-for-some-gastrointestinal-cancers 2024-10-25T11:31:38+00:00 weekly 0.7 https://trial.medpath.com/news/positive-pipeline-updates-for-friedreich-s-ataxia-managed-healthcare-executive 2024-10-25T11:27:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-pipeline-updates-for-friedreich-s-ataxia-managed-healthcare-executive 2024-10-25T11:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/jubilant-therapeutics-inc-announces-first-patient-dosing-in-global-clinical-trials-for-jbi 2024-10-25T11:26:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jubilant-therapeutics-inc-announces-first-patient-dosing-in-global-clinical-trials-for-jbi 2024-10-25T11:26:26+00:00 weekly 0.7 https://trial.medpath.com/news/impact-biotech-to-present-updated-interim-phase-3-data-from-globenewswire 2024-10-25T11:17:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/impact-biotech-to-present-updated-interim-phase-3-data-from-globenewswire 2024-10-25T11:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/sonara-health-rolls-out-remote-monitoring-app-to-tackle-methadone-drop-out 2024-10-25T11:09:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sonara-health-rolls-out-remote-monitoring-app-to-tackle-methadone-drop-out 2024-10-25T11:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/everest-medicines-announces-the-launch-of-velsipity-r-in-the-guangdong-hong-kong 2024-10-25T10:57:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/everest-medicines-announces-the-launch-of-velsipity-r-in-the-guangdong-hong-kong 2024-10-25T10:57:39+00:00 weekly 0.7 https://trial.medpath.com/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T10:57:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T10:57:25+00:00 weekly 0.7 https://trial.medpath.com/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T10:54:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ani-pharmaceuticals-announces-the-fda-approval-and-launch-of-estradiol-gel-0-06 2024-10-25T10:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/digital-twins-of-cancer-patients-predict-effectiveness-of-treatments-the-engineer 2024-10-25T10:46:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/digital-twins-of-cancer-patients-predict-effectiveness-of-treatments-the-engineer 2024-10-25T10:46:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-medtronic-s-affera-mapping-and-ablation-system-with-sphere-9-catheter 2024-10-25T10:43:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-medtronic-s-affera-mapping-and-ablation-system-with-sphere-9-catheter 2024-10-25T10:43:27+00:00 weekly 0.7 https://trial.medpath.com/news/eyepoint-stock-gains-traction-with-new-amd-trials-jefferies-sees-65-upside-investing-com 2024-10-25T10:38:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eyepoint-stock-gains-traction-with-new-amd-trials-jefferies-sees-65-upside-investing-com 2024-10-25T10:38:08+00:00 weekly 0.7 https://trial.medpath.com/news/nice-rejects-second-alzheimer-s-drug-but-opportunity-remains-for-decision-change-globaldata 2024-10-25T10:33:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-rejects-second-alzheimer-s-drug-but-opportunity-remains-for-decision-change-globaldata 2024-10-25T10:33:06+00:00 weekly 0.7 https://trial.medpath.com/news/assessing-the-impact-of-immersive-virtual-reality-technology-on-the-psychological-recovery-trials 2024-10-25T10:26:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/assessing-the-impact-of-immersive-virtual-reality-technology-on-the-psychological-recovery-trials 2024-10-25T10:26:25+00:00 weekly 0.7 https://trial.medpath.com/news/what-works-best-to-ease-ms-linked-fatigue-new-study-finds-out 2024-10-25T10:10:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/what-works-best-to-ease-ms-linked-fatigue-new-study-finds-out 2024-10-25T10:10:34+00:00 weekly 0.7 https://trial.medpath.com/news/are-elimination-diets-much-help-against-child-eczema 2024-10-25T10:10:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-elimination-diets-much-help-against-child-eczema 2024-10-25T10:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/modalis-therapeutics-has-received-an-orphan-drug-designation-from-the-u-s-food-and 2024-10-25T10:04:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/modalis-therapeutics-has-received-an-orphan-drug-designation-from-the-u-s-food-and 2024-10-25T10:04:42+00:00 weekly 0.7 https://trial.medpath.com/news/monopar-announces-agreement-with-alexion-astrazeneca-rare-disease-for-late-stage 2024-10-25T10:00:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/monopar-announces-agreement-with-alexion-astrazeneca-rare-disease-for-late-stage 2024-10-25T10:00:53+00:00 weekly 0.7 https://trial.medpath.com/news/novocure-s-wearable-device-receives-fda-approval-for-metastatic-cancer-treatment 2024-10-25T09:51:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novocure-s-wearable-device-receives-fda-approval-for-metastatic-cancer-treatment 2024-10-25T09:51:45+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-announces-dosing-of-first-participant-in-phase-1-clinical-trial-of-kt 2024-10-25T09:50:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-therapeutics-announces-dosing-of-first-participant-in-phase-1-clinical-trial-of-kt 2024-10-25T09:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-gets-green-light-to-move-onto-phase-2-portion-of-trial-evaluating-stargardt-gene 2024-10-25T09:41:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-gets-green-light-to-move-onto-phase-2-portion-of-trial-evaluating-stargardt-gene 2024-10-25T09:41:39+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-linked-with-lower-risk-of-alzheimer-s-diagnosis-medpage-today 2024-10-25T09:19:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-linked-with-lower-risk-of-alzheimer-s-diagnosis-medpage-today 2024-10-25T09:19:23+00:00 weekly 0.7 https://trial.medpath.com/news/vaccinex-to-report-promising-new-efficacy-data-for-signal-ad-phase-1b-2-trial-of-biospace 2024-10-25T09:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaccinex-to-report-promising-new-efficacy-data-for-signal-ad-phase-1b-2-trial-of-biospace 2024-10-25T09:03:13+00:00 weekly 0.7